ATP3 Guidelinesose Range: 4-8 m @ @ @applATP34codeXcode!HtFRM)data*xTalt +JTalt ,Talt4,Talt `-[Talt-Talt .Talt/(Talt/Talt (0BTalt0Talt1HTalt 1Taltl2DTalt T2Talt 3/tFRM3code3tver3v0003i0003i0018i002P+i002@i003Iv004Wi004]i004i004v005i005v006i006i007rctlsrnumbrdupercatsrlnchrsizerask stAINstAIBs tAIBv#datv#addvversvdelevdescvozNV/vHn?<// NO- n /NO!(POf$?*(/* ?*$NOI&H/ NOJ CBpO `pLN^NuOpenAndLockResourceNVH8(n&n $nBHnHn/ / N6OfJf0` *Ѯ(.*ct//./ NO&*/ N8/HnHn/ / N6O$fJf0`v//.AH/NO&%E .O b / NXO`H/NO"/NOaPO`8//./ NO& Ѫ .O b / NXO`/NO"/NOaPO0L8N^NuWriteDBNVH8:.(.ACp"Q(nJfp`N$Bg/ gAHP/ Hn?< NO6O`AHPAHPHn?< TNO6O g/ NOXO< Cgz Ff|0/?NOBJ@\Ofp`^AHPAHPHn?<lNOO`> g/ NOaXO/?NOBJ@\Ofp`"AbHPA^HP/.?<lNOpO`pLxN^NuDeleteDB2NV/ $n` ?< / NO$H \Of$_N^NuRemoveSquaresNVH8BnvACp2Q n /<BHnNO/<n /<xHnNOHnHnNO"n"BgHnNOHn?<NO<NOdN?</vTO`2??NO r2(?NO>J\OfHnHn?NO ܮO RCGeRENO:@e LN^NuGetAvailMemoryNVpN^NuMainFormHandleEventNV/ / HnHnNOJPOgJ?</.?.NOI$H POg2Bg/N^NuNV/ `+R?v8O6`P/ NOg:HnHnHn?/ NOh codeOf nfRC`?/ NOm/ NOg@O fRCRDGe/ NOJJFXOfxNJgpNJghB'HxHnNO'-|dbs-A-H-nHnHnNO-n-|applHn/ N-@=n=n?<0HnNOVO L N^NuDeleteSelf2  bp t 9- OK - ICancelt NANA(NANARNAXNANANA NA\NANAtNANB NA NA((ELBhB`EMbEE(E8EP DzE:NBtE CBrC@@Database ExistsA database named "^1" with version ^2 already exists. Do you want to replace it with this unknown version? (No version info found.)ReplaceReplace AllCancelFramework CachedYou cannot install this PatientKeeper update until you first disable the PatientKeeper "Framework Cache". Please refer to the documentation for details.OKDatebook Database BusyThe datebook database is in use by another application. Please deactivate any programs that may be using the datebook database.OKAddress Database BusyThe address database is in use by another application. Please exit any applications that may be using the address database.OKDatabase ExistsA database named "^1" with the same version number (^2) already exists. Do you want to replace it?ReplaceReplace AllCancelDatabase ExistsA database named "^1" with version ^2 already exists. Do you want to replace it with version ^3?ReplaceReplace AllCancelSystem IncompatibleThis device's Palm OS version is below mimimum requirements. Please refer to product documentation for details.OKNot Enough MemoryThis installer requires more memory than is currently available on this device. No data has been installed.OKDatabase ExistsA database named "^1" already exists. Do you want to replace it with version ^2?ReplaceReplace AllCancelAddress Database ErrorThere was a problem opening the Address Book database. No new address records were installed.OKDatebook Database ErrorThere was a problem opening the Datebook database. No new datebook records were installed.OKReset RequiredYou have installed software that requires you to reset your device by tapping the button below.ResetCannot Replace DatabaseThe database named "^1" cannot be replaced, because the original cannot be deleted.OKDatabase ExistsA database named "^1" already exists. Do you want to replace it?ReplaceReplace AllCancelUnsupported SystemThis software is not compatible with the Palm OS 5.0 or higher.OKh ?<1.11.13SFE_ScreenLockrror ^1: ^2Ok ,G7,G7,G7ExtnSMSEtverxcode}codedata1.13HzNuNXNSFX2zh^::.__Startup__NVpN^NuPilotMainNVA . pN^NuSF_LinkPtrNV/ /?<HxNXO hjN$H/ ?<Hz@HxNXO hNB'Hx/ NO'HxNBHn?</XO hNHn/./.HxN"XO?NO-n-n/./.HxNXO hNO` >HnHxNXO hNB/XO?NO-n-n/./.HxNXO hNO`ZHnHxNXO hNHxNXO hN4Hn?/./.HxNXO?NO-n-n/./.HxNXO hNO`HnHxNXO hNBB/./.t(NOJOg?<NB-n-nTO` Hn/./.HxN>XO?NOO-n-n/./.HxNXO hNPO`XHnHxNXO hNBB/./.t(NOJOg?<N-n-nTO` Hn/./.HxNXO?NOO-n-n/./.HxNXO hNPO`HnHxNlXO hNHxN\XO hN6Hn0C/HntNOPO/(/(B/<@$HxN&XO?NO/./././.Hnt4NOHn/./.HxNXO?NO1/./././.Hnt6NO/./.HxNXO hNOX`HnHxNXO hNHn/./.HxNXO?NO"-n-n/./.HxNbXO hNO`HnHxNFXO hNBB/./.t'NOJOg?<N-n-nTO` Hn/./.HxNXO?NOO-n-n/./.HxNXO hNPO`HnHxNXO hNHnHxNXO hN/./.BBt%NOJOg2BB/./.t'NOJOg?<N>-n-nTO`t/./.BBt%NOJOg2/./.BBt%NOJOg?<N-n-nTO`(Hn/./././.HxNXO?NOO-n-n/./.HxNXO hNPO`BBHnHxNXO hNHnHn/./.HxN|XO?NO/./.tNOHPO/HxNXXO hNO`BBHnHxN4XO hNHnHn/./.HxNXO?NO-n-n/./.HxNXO hNO`0HnHxNXO hNBB/./.t(NOJOg?<N-n-nTO` Hn/./.HxNXO?NOO-n-n/./.HxN^XO hNPO`HnHxNDXO hNHn/./.HxN(XO?NO -n-n/./.HxNXO hNO`DHnHxNXO hNHn/./.HxNXO?NO%0n/HxNXO hNO`HnHxNXO hNHn/./.HxN~XO?NO-n-n/./.HxNZXO hNO`HnHxN>XO hNHnHxN*XO hNHn/./././.HxNXO?NO(-n-n/./.HxNXO hNO&`"HnHxNXO hNBB/./.t(NOJOg(?<N|/./.HxNXO hNO `Hn/./.HxNhXO?NO,0n/HxNRXO hNO`HnHxN6XO hNHnHxN"XO hNHn/./././.HxNXO?NO*-n-n/./.HxNXO hNO&`/A|HPHxNXO hNPOLN^NuOnSfxNotifyzSF Math Library Extension Version 5.2.1 Copyright (c) 2000-2003 Pumatech, Inc.Internal error: Unknown method called - NV0n/AHPHxN XO hN0.PO@g@ g@gbS@g U@g$Q@g<`AHPHxNXO hNXO`AHPHxNXO hNXO`AHPHxNXO hNXO`fAHPHxNvXO hNXO`LAHPHxN\XO hNXO`2AHPHxNBXO hNXO`A8HPHxN(XO hNXON^NuErrorMsgs2Error Error: Can not pass a value of zero.Error: Out of domain boundaries.Error: Greater than machine limits.Error: This is not an SFX control.Error: Could not find MathLib. Please download MathLib.prc.Error: Can not open MathLib. Please reload MathLib.prc.Error: Invalid value(s) passed((0 ?<Eatp30000$ATP_3$J,F,F,FF`FORMatp3"4d\ B&-49> C G Q Y~ agknjt2w|>XbX6=EB E!E"SFAPATP 3P  + SDDI_PalmDBSDDIEatp30000_ATP3T1 CSFE_MathSFE_ScreenLockFORM$$ ,MPa1yFPa1yTPa1yTPa1y TPa1yPa yTPa y TPa1y UayUayUayUayqQqASAa q `PqUa zq `*Paz q ` qQqeSAa q `Pq Ua zq `)Paz q ` qQqdSAa q `Pq Ua zq `)Paz q ` qQa q `;q Uaz  q `z   qPqPAa qPa `T qPa `T qPa `T qPa ` qPa `T q Pa `T CTRL$f DR](other clinical atherosclerotic dzCTRL$T DGTRestablished CHDCTRL$(D"-TC:CTRL$(D"0/CTRL$FD&Back CTRL$^DRiskAssess q CTRL$N D]6hdiabetesCTRL$R DhIscigarette useCTRL$X Dsh~HTN (or Rx for HTN)CTRL$V D~ZFm Hx early CHD kCTRL$,D:6bAGender:CTRL$*D6AAge:CTRL$*D4"J-LDL:CTRL$Dy Assess qSqdQ@qS@qPqPA@qS@q@Q@qS@aTotal cholesterol (130-320), LDL, HDL (20-100), age (>= 20), gender, and risk factors are required inputs for evaluation of CHD risk statusBpq q q q qPaT `F qPaT `F qPaT `F qPa  ` qPaT `F q PaT `F F RiskAssess qPqP@qP@aq qQq(SAa 0 q30   *  &      ! " # $ % ( ) *q` RaM  *  &      ! " # $ % ( ) *q`[Pa<1   *  &      ! " # $ % ( ) *qeCTRL$FD&Back=CTRL$4DRAdditional dataCTRL$FDThe following additional data is CTRL$JD)required to assess this individual'sCTRL$FD)410-year CHD risk with FraminghamCTRL$2DD?OSystolic BP:CTRL$*DvCNmmHgCTRL$4DXUcOn Rx for HTN?:CTRL$` LZWfdYy  CTRL$` LhWtdNy  CTRL$.D4#?scoring:6CTRL$(DRCpPFORM$$r :yCHD CTRL$.Da3>LDL levelCTRL$4DO;Zinitiate TLC: CTRL$*D&Q6\_ _ _CTRL$XDCHD q CTRL$DDhs(100-129 mg/dL: drug optional) CTRL$jD&BackFramePaq`qCTRL$DNLDL lowering txRa q`dSa q`qCTRL$4D>Risk category:CTRL$>DCHD & CHD Risk EquivalentCTRL$8D[*(10-year risk >20%)CTRL$2D3=>For category:CTRL$HD7B__________________________________.CTRL$0DA/LLDL goal: CTRL$0DXAL< 100 mg/dLCTRL$HDEP__________________________________9CTRL$2DROZ>= 100 mg/dL CTRL$6D]Khconsider drug tx:CTRL$2DR]h>= 130 mg/dL CTRL$HDmx__________________________________CTRL$4D|>patient's LDL:6CTRL$(EA[|nCTRL$*Dq|mg/dLCTRL$HDS^__________________________________CTRL$D&P8[9'Therapeutic Lifestyle Changes': ATP III's lifestyle approach to cholesterol lowering and CHD risk reduction. BSee info menu for details.BpFORM$$l 4yCTRL$.Dd3>LDL levelCTRL$8DX0 - 1 Risk factor CTRL$8D[*(10-year risk <10%)CTRL$DDkv(160-189 mg/dL: drug optional) CTRL$4DQ;\initiate TLC: CTRL$*D&S6^_ _ _CTRL$XD0-1 q CTRL$rDQLDL lowering txRaq`qCTRL$4D>Risk category:CTRL$FD&BackCTRL$0DB/MLDL goal: CTRL$6D`Kkconsider drug tx:CTRL$2DU`k>= 190 mg/dL CTRL$0D[BM< 160 mg/dLCTRL$2DUQ\>= 160 mg/dLDCTRL$HDFQ___________________________________CTRL$HDU`___________________________________CTRL$HDoz___________________________________CTRL$4D~>patient's LDL:$CTRL$(EA^~qCTRL$*Dt~mg/dLCTRL$2D3=>For category:CTRL$HD7B___________________________________CTRL$D%R8]_'Therapeutic Lifestyle Changes': ATP III's lifestyle approach to cholesterol lowering and CHD risk reduction. BSee info menu for details.BplFORM$$r :yyCTRL$4DQ;\initiate TLC: CTRL$*D%S5^_ _ _CTRL$.Dd3>LDL levelCTRL$4DD10-yr CHD risk:CTRL$(EA^qCTRL$&Dt|%CTRL$ZD2+<10 q CTRL$8D[*(10-year risk <10%)CTRL$6DT2+ Risk factorsCTRL$4D>Risk category:$CTRL$0DB/MLDL goal: CTRL$6D`Kkconsider drug tx:CTRL$2DU`k>= 160 mg/dL CTRL$0D[BM< 130 mg/dLCTRL$2DUQ\>= 130 mg/dLCTRL$HDFQ__________________________________$CTRL$HDU`__________________________________CTRL$HDdo__________________________________CTRL$4Dr>}patient's LDL:HCTRL$(EA^rqCTRL$*Dtr}mg/dLCTRL$2D3=>For category:CTRL$HD7B__________________________________$CTRL$rDNLDL lowering txRaq`q_CTRL$FD&BackCTRL$D&Q7^ 'Therapeutic Lifestyle Changes': ATP III's lifestyle approach to cholesterol lowering and CHD risk reduction. BSee info menu for details.BpFORM$$r :CHD100-129 CTRL$JD EP weight loss & physical activity in5CTRL$@DOZpt's w/ metabolic syndromeeCTRL$BD-Q\_ _ _ _ _ _ _ _ _ _ _ _ _ _ ECTRL$JD 8C initiate/intensify TLC and/or drugZCTRL$*DX:hE_ _ _CTRL$|D&BackLCHDPaq`CHDfromFramePaqCTRL$ND2nHospitalized?CTRL$^DCHD100-129 q CTRL$HD"-OPTIONS when LDL is 100-129 mg/dLCTRL$>DCHD & CHD Risk EquivalentCTRL$FD\gdelay LDL lowering tx. Tx other_CTRL$DDf|qlipid & nonlipid risk factors._CTRL$>DLDL-lowering therapy forCTRL$BD,w7at baseline or on treatment:CTRL$FD p{ Consider other lipid modifying CTRL$HDzdrugs (nicotinic acid, fibric acid)CTRL$6DYfor high HDL & TGCTRL$DW8hEr'Therapeutic Lifestyle Changes': ATP III's lifestyle approach to cholesterol lowering and CHD risk reduction. BSee info menu for details.BpCTRL$D,Q\aka 'Syndrome X': a constellation of lipid and nonlipid risk factors of metabolic origin. BSee info menu item for details.BplFORM $$p 8CHD>130 CTRL$ND2nHospitalized?CTRL$\DCHD>130 q CTRL$>DLDL lowering therapy forCTRL$|D&BackrCHDPaq`CHDfromFramePaqCTRL$>DCHD & CHD Risk EquivalentCTRL$BD(3When baseline LDL >=130mg/dL:CTRL$>D 9wD intensive TLC & maximalCTRL$BDEPcontrol of other risk factorsCTRL$BD V|a initiate LDL-lowering drug0CTRL$<Dbumsimultaneously with TLCCTRL$*D8;HF_ _ _CTRL$D7;HEr'Therapeutic Lifestyle Changes': ATP III's lifestyle approach to cholesterol lowering and CHD risk reduction. BSee info menu for details.BpFORM$$t <CHDbase<100 CTRL$BD kv treat metabolic syndrome, CTRL$BD+mx_ _ _ _ _ _ _ _ _ _ _ _ _ _ CTRL$FD AL TLC diet to maintain LDL < 100CTRL$*DC#N_ _ _CTRL$|D&BackCHDPaq`CHDfromFramePaqCTRL$ND2nHospitalized?CTRL$`DCHDbase<100 q CTRL$0Du;if presentoCTRL$>DCHD & CHD Risk EquivalentCTRL$>DLDL-lowering therapy foruCTRL$BD*When baseline LDL <100 mg/dL:CTRL$FD 0; LDL-lowering drug NOT requiredCTRL$JD Q\ control other lipid and non-lipid eCTRL$2D[Bfrisk factorsnCTRL$DB$O'Therapeutic Lifestyle Changes': ATP III's lifestyle approach to cholesterol lowering and CHD risk reduction. BSee info menu for details.BpCTRL$D+mxaka 'Syndrome X': a constellation of lipid and nonlipid risk factors of metabolic origin. BSee info menu item for details.Bp FORM$$d ,CTRL$@D juu use clinical judgment forCTRL$@DtLDL-lowering drug when LDL CTRL$FD Q\ discharge on TLC & LDL-loweringCTRL$*DGSW^_ _ _CTRL$6D~Zis 100-129 mg/dLCTRL$8DCZNor within 24 hoursqCTRL$\DCHDHosp q CTRL$D&BackCHD>130Paq`CHD100-129Paq`qCTRL$>DCHD & CHD Risk EquivalentCTRL$<D{LDL lowering therapy inCTRL$HD(3When pt hospitalized for CHD event:CTRL$@D 9}D measure LDL at admission CTRL$<D\zgdrug if LDL >=130 mg/dLCTRL$DFRX^i'Therapeutic Lifestyle Changes': ATP III's lifestyle approach to cholesterol lowering and CHD risk reduction. BSee info menu for details.BpFORM$$d ,CTRL$>DDrug therapy to lower LDLCTRL$FDWhen drugs are employed to lower CTRL$HD*LDL, attention to TLC should alwaysCTRL$BD+~6be maintained and reinforced.CTRL$HD <G drugs affecting lipid metabolism4CTRL$DD OZ drug tx for CHD & EquivalentsCTRL$DD do drug tx in primary preventionCTRL$FDCN---------------------------------CTRL$DDVa-------------------------------CTRL$DDkv-------------------------------CTRL$BD<K CTRL$FD&BackD@CTRL$BDcrCTRL$BDO^FORM&&$$d ,CTRL$<DsBile acid sequestrantsDCTRL$<DlDrugs affecting lipid eCTRL$0D?metabolismCTRL$DD %0 HMG CoA reductase inhibitorsCTRL$.D46?(statins)CTRL$DD,7------------------------------DCTRL$.D;4F-------- CTRL$BD$ACTRL$>DFlQ bile acid sequestrants-CTRL$<DMlX----------------------CTRL$6DXGc nicotinic acidCTRL$2D_Hj-------------CTRL$4Dj?u fibric acidsCTRL$0Dq<|----------CTRL$FD&BackD@CTRL$VDDoTDy CTRL$VDVhfiy cCTRL$VDhhxky CTRL$.D5(statins)CTRL$LD"______________________________________xCTRL$( D%CTRL$BDHMG CoA reductase inhibitorsdCTRL$FD&Back CTRL$LD______________________________________CTRL$LD ______________________________________iCTRL$( G CTRL$ZD&Backsy CTRL$LD______________________________________CTRL$LD______________________________________*CTRL$( G CTRL$4DFNicotinic acidCTRL$ZD&Backy CTRL$LD______________________________________CTRL$LD______________________________________uCTRL$( G CTRL$2D:Fibric acidstCTRL$ZD&Backy CTRL$LD______________________________________`FORM$$d ,CTRL$D&Backi RiskAssessPaqCHDfromFramePaqMainPaq 0-1Paq0-1<160Paq0-1>160Paq2+ 10-20Paq2+ 10-20<130Paq2+ 10-20>130Paq 2+<10Paq2+<10<130Paq2+<10>130PaqCHDPaqCHD>130PaqCHD100-129PaqCHDbase<100PaqCHDHospPaqFramePaqCTRL$BDw! ATP III CHD risk assessmentCTRL$NDJU ATP III classification of lipid levelsCTRL$:D[]f metabolic syndromeCTRL$JD'2 Therapeutic Lifestyle Changes (TLC)CTRL$BD9mD drug tx for lipid loweringCTRL$6Dl>w special issuesCTRL$4DGAbout ATP III CTRL$@D v(---------------------------CTRL$JD /:-------------------------------------CTRL$>D{k how to use this programCTRL$>D @nK-------------------------CTRL$FD R]--------------------------------CTRL$:D c^n---------------------CTRL$2D s>~-------------CTRL$>D n-------------------------CTRL$BD{$_CTRL$BD8G_ CTRL$BD&6 CTRL$BDZjCTRL$BDkazCTRL$BDJYCTRL$BD{u FORM$$ ,zzz zz             False True F         CTRL$JLkcr Read 1st!CTRL$VDy +CTRL$8D# ATP III CholesterolCTRL$:D#)Management GuidelinesCTRL$FD(3________________________________ CTRL$BD 5@ Interactive guideline tool CTRL$FD=H--------------------------------CTRL$HDGRA tool to assist with implementingpCTRL$HDQ\the ATP III Cholesterol Guidelines CTRL$:D[_fat the point of careCTRL$FD | ATP III cholesterol informationCTRL$DD------------------------------TCTRL$0D?(text only)CTRL$BD4CCTRL$XDv@ Main q CTRL$HDPalm OS implementation tool for theCTRL$DDExecutive Summary of the Third CTRL$HD%Report of the National Cholesterol-CTRL$FD$/Education Program Expert Panel onCTRL$HD.9Detection, Evaluation, & TreatmentCTRL$HD8Cof High Blood Cholesterol in AdultsCTRL$<DBaM(NIH Pub. No. 01-3096)CTRL$JDQ\This program is in the public domainCTRL$DD[fand may be freely distributed.CTRL$6DitWWW.NHLBI.NIH.GOVCTRL$*DFtYv 2.0CTRL$VDDy CTRL$JD "-#SFRLRSRC:Eatp30000#ATP_3:Tbmp:3656FORM$$d ,CTRL$DD ju if present, turn attention toCTRL$>Dtmetabolic syndrome, afterCTRL$BDvf_ _ _ _ _ _ _ _ _ _ _ _ _ _ CTRL$@D >qI initiate & maintain TLC CTRL$*D`ApL_ _ _CTRL$`D2+ 10-20>130 q CTRL$FD&BackTCTRL$4DR2+ Risk factorsCTRL$>DLDL-lowering therapy for$CTRL$DD.9When baseline LDL >=130 mg/dL:LCTRL$:Dc*(10-year risk 10-20%)CTRL$FD OZ if LDL is >=130 after 3 months,CTRL$FDXcconsider adding LDL-lowering drugCTRL$@Dmaximal response to LDL txmCTRL$D_?pL'Therapeutic Lifestyle Changes': ATP III's lifestyle approach to cholesterol lowering and CHD risk reduction. BSee info menu for details.BpCTRL$DvgMaka 'Syndrome X': a constellation of lipid and nonlipid risk factors of metabolic origin. BSee info menu item for details.BpFORM $$d ,CTRL$`D2+ 10-20<130 q CTRL$FD&BackCTRL$4DR2+ Risk factorsCTRL$>DLDL-lowering therapy forACTRL$BD.9When baseline LDL <130 mg/dL:CTRL$>D=rH LDL is at or below goalCTRL$BDKV recommend physical activityCTRL$@DU`regimen & lifestyle changesCTRL$:Dc*(10-year risk 10-20%)CTRL$4D_Ujas appropriate:CTRL$BDmx control other risk factors$CTRL$:D{` periodic follow-upoFORM $$d ,CTRL$^D2+<10<130 q CTRL$FD&BackkCTRL$4DR2+ Risk factorsCTRL$>DLDL-lowering therapy forrCTRL$BD.9When baseline LDL <130 mg/dL:CTRL$>D =kH LDL is at or below goalCTRL$BD KV recommend physical activityCTRL$@DU`regimen & lifestyle changesCTRL$8D[*(10-year risk <10%)CTRL$4D_Njas appropriateaCTRL$BD mxx control other risk factorsoCTRL$:D {Y periodic follow-up-FORM$$d ,CTRL$>Dt~metabolic syndrome afterCTRL$@Dvd_ _ _ _ _ _ _ _ _ _ _ _ _ _CTRL$@D >rI initiate & maintain TLC CTRL$*D`@pK_ _ _CTRL$^D2+<10>130 q nCTRL$FD&BackCTRL$4DR2+ Risk factorsCTRL$>DLDL-lowering therapy foreCTRL$DD.9When baseline LDL >=130 mg/dL:eCTRL$FDYdconsider adding LDL-lowering drugCTRL$FD OZ if LDL is >=160 after 3 months,CTRL$8D[*(10-year risk <10%)CTRL$*D`CpN----oCTRL$DD ju if present, turn attention toCTRL$@Dmaximal response to LDL txCTRL$D_?pL''Therapeutic Lifestyle Changes': ATP III's lifestyle approach to cholesterol lowering and CHD risk reduction. BSee info menu for details.BpCTRL$Dvgaaka 'Syndrome X': a constellation of lipid and nonlipid risk factors of metabolic origin. BSee info menu item for details.BpaFORM $$d ,CTRL$\D0-1<160 q CTRL$FD&BackCTRL$4DR0-1 Risk factorCTRL$>DLDL-lowering therapy forCTRL$BD.9When baseline LDL <160 mg/dL:CTRL$>D=rH LDL is at or below goalCTRL$BDKV recommend physical activityCTRL$@DVaregimen & lifestyle changesCTRL$8D[*(10-year risk <10%)CTRL$4DaTlas appropriategCTRL$@Dlwcontrol other risk factorseCTRL$:D{` periodic follow-uprFORM$$d ,CTRL$@D=xH initiate & maintain TLC CTRL$*DaCqN----CTRL$\D0-1>160 q CTRL$FD&BackCTRL$4DR0-1 Risk factorCTRL$>DLDL-lowering therapy forDCTRL$DD.9When baseline LDL >=160 mg/dL:nCTRL$BDKV LDL-lowering drug optional CTRL$@DW~bif LDL is 160-189 after 3 rCTRL$8D[*(10-year risk <10%)CTRL$0DbJmmonths TLCoCTRL$DDp{ consider LDL-lowering drug ifCTRL$BD{LDL >=190 despite maximal TLCCTRL$D`>qJp'Therapeutic Lifestyle Changes' ATP III's lifestyle approach to cholesterol lowering and CHD risk reduction. BSee info menu for details.BpCTRL$D_=pJp'Therapeutic Lifestyle Changes': ATP III's lifestyle approach to cholesterol lowering and CHD risk reduction. BSee info menu for details.BpFORMjj$$d ,CTRL$DD Persons in the Multiple (2+) CTRL$DD&LDL-lowering tx is to obtain aCTRL$6D{Z(see Note below).CTRL$@D%q0lipoprotein profile, then CTRL$BD/:determine CHD risk category.CTRL$DD/: Assign to the CHD & CHD Risk$CTRL$@Dx&Risk Factors category are TCTRL$@DRisk assessment in ATP III CTRL$FD The first step in selection of CTRL$FDWb ATP III identifies 3 categoriesCTRL$2Da=lof CHD risk:CTRL$FDmx1. "CHD & CHD Risk Equivalents"CTRL$FDx2. " Multiple (2+) Risk Factors"CTRL$:D]3. "0-1 Risk Factor"CTRL$FD&Backp@ CTRL$FD>bNextmCTRL$*D(1/7)CTRL$*D(2/7)CTRL$@DRisk assessment in ATP IIIrCTRL$DD9DEquivalents category people whoCTRL$DDCNhave either established CHD orlCTRL$DDMXany of the CHD Risk Equivalent CTRL$HDWbconditions (see next), which carryoCTRL$DDalthe same risk of major coronaryCTRL$DDkvevent as CHD, i.e., > 20% per CTRL$DD The category of highest risk CTRL$DD&is CHD & CHD Risk Equivalents. CTRL$FD>bNextCTRL$FD&BackWCTRL$@DRisk assessment in ATP IIICTRL$*D(3/7)CTRL$DD  The CHD Risk Equivalents are:CTRL$@Ds*- clinical forms of ASCVD DCTRL$HD)4(peripheral arterial dz, abdominal(CTRL$DD3>aortic aneurysm, & symptomaticCTRL$8D=^Hcarotid artery dz)kCTRL$0DM7X- diabetesCTRL$HD\g- multiple risk factors that conferCTRL$@Dfqa 10-year CHD risk of > 20%CTRL$2DpE{(see below).tCTRL$*D(4/7)CTRL$@DRisk assessment in ATP IIICTRL$FD For individuals who do not fallCTRL$BD&into the CHD & CHD Risk Equi-CTRL$FD%0valents category, risk assessmentCTRL$DD/:is performed by first countingCTRL$DD9Dthe number of CHD risk factors:CTRL$8DI^T- cigarette smokingCTRL$FDS^- hypertension (or on Rx for HTN)CTRL$>D]sh- family Hx of early CHDCTRL$BDgr- age >= 45 for M, >=55 for FCTRL$<Dqn|- low HDL (< 40 mg/dL)aCTRL$FD>bNexteCTRL$FD&BackLCTRL$FD&BackCTRL$FD>bNextCTRL$@DRisk assessment in ATP IIItCTRL$*D(5/7)CTRL$FD&BackCTRL$FD>bNextDCTRL$@D~(Note: an HDL >= 60 countsCTRL$BD|&as a "negative" risk factor;tCTRL$BD%0its presence removes one riskCTRL$BD/:factor from the total count.)CTRL$FDCN Persons with a total of 0 or 1 CTRL$DDMXrisk factor are assigned to theCTRL$>DWtb0-1 Risk Factor category.CTRL$JDju Persons with 2 or more risk factorsCTRL$FDtare assigned to the Multiple (2+)CTRL$<D~hRisk Factors category.CTRL$@DRisk assessment in ATP IIIUCTRL$*D(6/7)CTRL$FD&BackrCTRL$FD>bNextCTRL$FD%0further classified by 10-year CHDCTRL$DD/:risk using Framingham scoring.lCTRL$@D9D(See the Executive SummaryCTRL$HD[f In ATP III Framingham scoring is CTRL$HDCNfor details on manually performingCTRL$:DMfXFramingham scoring.)CTRL$DDepused to classify persons in theCTRL$@Dy~10-year CHD risk of >20%, eCTRL$@DRisk assessment in ATP III CTRL$FD&BackCTRL$@D&Factor category who have auCTRL$DDVa Persons with 10-year risk ofsCTRL$BD`k10-20% or <10% remain in the CTRL$BDjuMultiple Risk Factor categoryCTRL$<Dtwbut recommendations forCTRL$*D(7/7)CTRL$DD Persons in the Multiple Risk CTRL$@D%010-year CHD risk of >20% onCTRL$DD>I Risk category determines LDLCTRL$DDHSgoal and treatment strategies.CTRL$<D/r:Framingham scoring are CTRL$>D9wDre-assigned to the CHD &CTRL$DDCNCHD Risk Equivalents category.CTRL$0D~4tx differ.eCTRL$XDyTopyCTRL$XDyTopyDCTRL$XDyTopy CTRL$XDyTopy>CTRL$XDyTopyCTRL$.Du410 years.CTRL$FDozMultiple Risk Factor category by CTRL$6DX10-20%, or <10%.*FORM;;$$d ,CTRL$DDzATP III's lifestyle approach toCTRL$2D PC[F/U q4-6 mos.CTRL$FD )LDL response. If LDL above goal,CTRL$HD (3consider drug tx. Initiate tx for$CTRL$4D FF/U in 6 weeks.CTRL$@Dt&cholesterol lowering & CHD CTRL$2DE'the TLC diet:CTRL$LD +______________________________________nCTRL$@D/'begin lifestyle therapies.tCTRL$4DDTLC in ATP IIICTRL$BD%t0risk reduction is designatedCTRL$BD/:Therapeutic Lifestyle ChangesCTRL$DD GR- reduced intakes of saturatedMCTRL$8DQY\fats & cholesterolCTRL$HD ^i- LDL lowering with plant stanols/kCTRL$HDhssterols and viscous (soluble) fiberCTRL$8D uT- weight reductionCTRL$FD&Back@ CTRL$FD>bNextICTRL$*D(1/4)CTRL$*D(2/4)CTRL$>DNutrient composition of CTRL$FD>bNextHCTRL$FD&Back$CTRL$*D(3/4)CTRL$>DA model approach to TLC: CTRL$0D.'VISIT 1: oCTRL$FD &1Emphasize reduction in saturated CTRL$DD 0;fat & cholesterol. ModeratelyCTRL$JD :Eincrease physical activity. ConsiderCTRL$*D(4/4)CTRL$FD>bNext$CTRL$FD&BackCTRL$FD&BackCTRL$HD9D(TLC). Its essential features are:CTRL$XDyTopyCTRL$XDyTopyTCTRL$BD |- increased physical activityCTRL$( E/ CTRL$4DDTLC in ATP III{CTRL$4DDTLC in ATP IIICTRL$,DR']VISIT 2CTRL$BD)R](at 6 weeks): evaluate LDL CTRL$HD \gresponse. If above goal, intensifyCTRL$FD fqLDL-lowering tx. Consider addingCTRL$FD p{plant stanols/sterols. Up fiberCTRL$@D zqintake. Consider dietitian.CTRL$@D DnOdietitian. F/U in 6 weeks.CTRL$,DKg(cont.)CTRL$4DDTLC in ATP IIINCTRL$>D)(at 12 weeks): evaluateDCTRL$,D'VISIT 3CTRL$DD 2=metabolic syndrome, if present.CTRL$FD <GIntensify weight mgmt & physicalCTRL$DD F{Qactivity. Consider dietitian. CTRL$0D`/kVISIT N: CTRL$:D/`kmonitor adherence to>CTRL$,D j uTLC. CTRL$LD______________________________________LFORMAA$$d ,CTRL$BD c~nhigh cholesterol. See the USCTRL$8DjMetabolic syndromeLCTRL$*D(5/5)CTRL$FD=aNext(CTRL$*D lwrisk.CTRL$.D 88Csyndrome.CTRL$BD~% Weight reduction & physicalCTRL$BD $y/activity will improve all theCTRL$DD .9risk factors of the metabolic CTRL$BDE{P ATP III recommends regularDCTRL$FD OZphysical activity in the mgmt ofkCTRL$BD Ydthe metabolic syndrome and/orCTRL$JD $/clinical guidelines for info on waysnCTRL$8DjMetabolic syndromeCTRL$*D(1/5)CTRL$FD #ATP III recognizes the metabolichCTRL$@D "-syndrome (aka "syndrome X")CTRL$BD ,7as a secondary target of riskCTRL$DD 6Areduction tx, after the primaryCTRL$FD&Back@ CTRL$FD>bNextCTRL$&D #CTRL$4D @CKtarget - LDL .CTRL$FD S^After appropriate control of LDL,CTRL$&DT ^CTRL$FD grpresent TLC should stress weight CTRL$DD q|reduction & physical activity.CTRL$BD ]hif the metabolic syndrome isoCTRL$8DjMetabolic syndrome CTRL$*D(2/5)CTRL$DDDiagnose the metabolic syndromeCTRL$HD&if 3 or more of these are present:CTRL$FD&BackD CTRL$FD>bNextDCTRL$<D(b3 waist circumference CTRL$<DPh[ HDL < 40 mg/dL (M), CTRL$BD 2v=> 40 in. (M), or > 35 in. (F)CTRL$BDAL triglycerides >= 150 mg/dLCTRL$4D ZJe< 50 mg/dL (F)CTRL$FD it blood pressure >=130/>=85 mmHg CTRL$DD x fasting glucose >= 110 mg/dLLCTRL$8DjMetabolic syndrome,CTRL$*D(3/5)CTRL$FD&Back  CTRL$FD>bNextvCTRL$FD .9to treat overweight and obesity.FCTRL$LD% See the Obesity Education InitiativeCTRL$@D mxSurgeon General's Report onCTRL$@D wrPhysical Activity for info.CTRL$FDNY Specific treatment of lipid & CTRL$BD Xycnonlipid risk factors of the CTRL$DD bmmetabolic syndrome will reduce CTRL$8DjMetabolic syndromeLCTRL$*D(4/5)CTRL$FD&BackF CTRL$FD% Treatments for lipid & nonlipidCTRL$:D$]/risk factors include:CTRL$6D1P<- control of HTNCTRL$DD=H- use of aspirin in pt's w/ CHDCTRL$@DIT- treatment of elevated TGCTRL$.DS>^& low HDLCTRL$XDyTopy~CTRL$XDyTopyaCTRL$FD&Back0 CTRL$XDyTopy$FORM $$d ,CTRL$6D[Drug therapy for CTRL$>DCHD & CHD Risk EquivalentCTRL$HD* Most pt's in this category will CTRL$DD )4need LDL-lowering drug therapyCTRL$DD8{C If baseline LDL is below goalCTRL$HD BM(i.e., <100), further LDL-loweringBCTRL$2D L?Wnot required CTRL$BD[f LDL-lowering drug tx can beCTRL$FD epstarted at same time as TLC whengCTRL$BD ozLDL >= 130, & optionally whenCTRL$0D y@LDL 100-129CTRL$FD&Back@FORM$$d ,CTRL$6DX,7See "drug tx forCTRL$2Da7BCHD & Equivs"CTRL$2DkLDL level to CTRL$2D;&Risk categoryCTRL$6DX'consider drug txTCTRL$LD!,______________________________________CTRL$>DDrug tx for 1 preventionCTRL$FD&Backu@CTRL$4DF@Q2+ Risk FactorsCTRL$8DQT\(10-20% 10-yr rsk)LCTRL$2DbFQ>= 130 mg/dL=CTRL$LDT_______________________________________LCTRL$4D_@j2+ Risk FactorsCTRL$6DjLu(<10% 10-yr rsk)8CTRL$2Da_j>= 160 mg/dLTCTRL$2Dbw>= 190 mg/dLCTRL$LDmx______________________________________CTRL$4Dw@0-1 Risk FactorCTRL$8DQ(160-189 optional)fCTRL$LD______________________________________TCTRL$4D,@72+ Risk FactorsCTRL$6D7NB(> 20% 10-yr rsk)CTRL$LD;F______________________________________$FORM>>$$d ,CTRL$,DL p+(mg/dL)CTRL$,DY!},(mg/dL)CTRL$,Da!,(mg/dL)CTRL$,DY!},(mg/dL)CTRL$>DvATP III classification ofCTRL$2D8lipid levelsCTRL$4D!T,LDL cholesterolCTRL$@D2X=<100 ............. optimalFCTRL$JDAL100-129 ...... near or above optimalDCTRL$DDPu[130-159 ...... borderline highCTRL$8D_Ij160-189 ...... highCTRL$>Dn^y>= 190 ....... very highCTRL$HD&1___________________________________CTRL$HD5@___________________________________CTRL$HDDO___________________________________CTRL$HDS^___________________________________CTRL$HDbm___________________________________CTRL$HDq|___________________________________CTRL$FD&Back_@ CTRL$FD>bNext CTRL$>DvATP III classification ofCTRL$2D8lipid levels$CTRL$6D!],Total cholesterolCTRL$BD2^=<200 ............. desirableLCTRL$DDAwL200-239 ....... borderline highCTRL$<DPL[>= 240 .......... high|CTRL$FD&1________________________________CTRL$FD5@________________________________CTRL$FDDO________________________________TCTRL$FDS^________________________________LCTRL$FD&Backe CTRL$FD>bNextCTRL$XDyTop y(CTRL$>DvATP III classification ofCTRL$2D8lipid levelsDCTRL$4D!V,HDL cholesterolCTRL$DD&~1______________________________CTRL$<D2C=< 40 ............. lowFCTRL$:DAGL>= 60 .......... highCTRL$DD5~@______________________________/CTRL$DDD~O______________________________*CTRL$FD&Back CTRL$FD>bNextCTRL$XDyTop yhCTRL$2D8lipid levelsCTRL$>DvATP III classification ofCTRL$2D H+TriglyceridesCTRL$BD%v0____________________________FCTRL$>D1V<<150 ............. normalCTRL$BD4v?____________________________CTRL$DD@uK150-199 ...... borderline highCTRL$BDCvN____________________________CTRL$8DOIZ200-499 ...... highCTRL$BDRv]____________________________CTRL$FD&Backn CTRL$XDyTop yHCTRL$>D^_i>= 500 ........ very highCTRL$BDawl____________________________aCTRL$*D(4/4)CTRL$*D(3/4)CTRL$*D(2/4)CTRL$*D(1/4)FORM $$d ,CTRL$>D)t4HDL (20-100 mg/dL), LDL,YCTRL$XDyTop yYCTRL$:D#C.PT: patientCTRL$DD/h:TC: total cholesteroliCTRL$,DPevel.CTRL$HDOZLDL: low-density lipoproteinCTRL$HD7BHDL: high-density lipoproteinCTRL$BD@rKAdditionally, systolic bloodbCTRL$@DJUpressure (90-200 mmHg) and CTRL$BDT_HTN treatment status may alsoCTRL$HD^ibe required (see "ATP III CHD risk_CTRL$BDhsassessment" info menu item)._CTRL$JD3>age (20-99), gender, & risk factors._CTRL$HD Required inputs for the interactiveCTRL$DD*module are TC (130-320 mg/dL),_CTRL$FD=aNext CTRL$6DS8^W/: withCTRL$2DKthis program.CTRL$FD=aNext CTRL$<DHow to use this programCTRL$HDThis program is a tool to assist inCTRL$>Ds'implementing the NationalCTRL$FD&1Cholesterol Education Program's CTRL$JD0;Adult Treatment Panel III (ATP III) hCTRL$JD:Eclinical guidelines for cholesterol TCTRL$BDDOtesting and management at theCTRL$>DZeUsers must be thoroughly_CTRL$BDdofamiliar with the guidelines_CTRL$@Dnybefore making any clinicalCTRL$8Dxcdecisions based on CTRL$4DN=Ypoint of care.yCTRL$FD&Back@ CTRL$FD=aNext  CTRL$<DHow to use this programCTRL$@DyThe interactive module usesCTRL$BD)patient data to determine theCTRL$BD(3CHD risk category, & providesCTRL$DD2=the relevant ATP III treatment_CTRL$BD<Grecommendations according to_CTRL$DDFQrisk category & LDL cholesterolCTRL$BDvky CTRL$DDlvwATP III is available from the CTRL$FDalInformation about all aspects of CTRL$FDvbutton on each of the interactiveCTRL$,D pages. CTRL$<DHow to use this programCTRL$@DAbbreviations & definitionsCTRL$<DHow to use this programCTRL$<DC]NHTN: hypertensionCTRL$<D+a6Fm Hx: family historyCTRL$<D;RFTx: treatment$CTRL$DD[|f"Other clinical atheroscleroticCTRL$:D/e|pperipheral arterial CTRL$FD*CHD: coronary heart diseaseCTRL$HDozdisease, abdominal aortic aneurysm,CTRL$HDysymptomatic carotid artery disease.CTRL$.De+pdisease":CTRL$FD&Back CTRL$FD=aNext CTRL$FD&Back CTRL$FD=aNextF CTRL$XDyTop yCTRL$FD&Back CTRL$XDyTop ynCTRL$*D(6/9)CTRL$*D(4/9)CTRL$*D(3/9)CTRL$*D(1/9)CTRL$<DHow to use this programCTRL$*D(8/9)CTRL$BDuTo use this program the fileICTRL$FD)MathLib.prc must be installed on CTRL$HD(3the Palm OS device. MathLib is a CTRL$FD2=free shared library distributed CTRL$HD<Gunder the terms of the GNU General CTRL$LDFQPublic License and can be obtained at:CTRL$<DV{ahttp://www.radiks.net/CTRL$<Dal~rhuebner/mathlib.htmlCCTRL$FD&Backf CTRL$<DHow to use this programCTRL$*D(9/9)CTRL$BD~For more information see the CTRL$DD)Executive Summary of the Third CTRL$HD(3Report of the National CholesterolTCTRL$FD2=Education Program Expert Panel onCTRL$HD<GDetection, Evaluation, & TreatmentDCTRL$HDFQof High Blood Cholesterol in AdultsCTRL$<DPc[(NIH Pub. No. 01-3096),CTRL$@DYhdor visit us on the Web at:CTRL$6D"jyuWWW.NHLBI.NIH.GOVCTRL$FD&BackL CTRL$XDyTop yeCTRL$<DHow to use this programCTRL$*D(7/9)CTRL$@DAbbreviations & definitionsCTRL$>DGVRTG: triglycerideCTRL$XDyTop yeCTRL$FD&Backo CTRL$FD=aNext CTRL$XDyTop yCTRL$<DHow to use this programCTRL$*D(2/9)CTRL$FD&Backy CTRL$FD=aNext CTRL$DDzThe first step in selection of CTRL$DD)LDL-lowering tx is to obtain a CTRL$FD(3fasting lipoprotein profile, thenCTRL$BD2=determine CHD risk category.JCTRL$FDALATP III treatment recommendationsCTRL$DDKVare based on risk category andDCTRL$<DU\`LDL cholesterol level.CTRL$JDdoThis program contains an interactive_CTRL$DDnymodule that assists the user inCTRL$FDxdetermining patient risk categoryCTRL$@Dand recommended treatment.oCTRL$<DHow to use this programCTRL$*D(5/9)CTRL$FD&Backo CTRL$FD=aNext CTRL$XDyTop y_CTRL$BD Note, this program performs CTRL$BD*Framingham risk scoring usingCTRL$HD)4an equation. Other NCEP materials,CTRL$JD3>such as ATP III print products, use aCTRL$FD=Hpoint-based system to calculate aCTRL$FDGRrisk score that approximates the CTRL$8DQY\equation-based one.FORMMM$$d ,CTRL$DD LW Favorable effects of statins CTRL$6D_)Men >= 65 years &CTRL$6D(b3women >= 75 yearsCTRL$@DSpecial considerations forCTRL$@Ddifferent population groupsCTRL$*D(1/6)CTRL$8Dk*Men age 35-65 yearsCTRL$FD&BackeCTRL$BD-|8 High prevalence of CHD riskCTRL$<D 7`Bfactors in this group.LCTRL$:D!{,Women age 45-75 yearsCTRL$FD 0; Most CHD in women occurs after CTRL$.D:0Eage 65. CTRL$<DVramake LDL-lowering drugCTRL$<D`nkpreferable to hormone CTRL$BDjureplacement tx for CHD risk CTRL$8Dt_reduction in women.CTRL$@DSpecial considerations forCTRL$*D(2/6)CTRL$@Ddifferent population groupsCTRL$HD7B No absolute age restrictions forCTRL$FD&BackuCTRL$FDALLDL-lowering tx in older persons>CTRL$:DKdVwith established CHD.CTRL$FDZ~e TLC is first-line of tx for 1LCTRL$BDdoprevention in older persons.ICTRL$FDs~ LDL-lowering drugs can also besCTRL$DD}considered for older persons atCTRL$@D s+higher risk (multiple risk CTRL$@DSpecial considerations forlCTRL$*D(3/6)CTRL$@Ddifferent population groupsCTRL$6DFbQMen 20-35 years &CTRL$6DPe[women 20-45 yearsCTRL$FD&BackCTRL$XDyTopyrCTRL$FD]h Institute TLC for young adultsCTRL$<Dgrrwith LDL >=130 mg/dL. CTRL$BDan LDL 160-189 mg/dL may be oCTRL$HD*candidates for LDL-lowering drugs.tCTRL$BD.9 Young adults with LDL >=190CTRL$BD8Cshould be considered for drugCTRL$<DBeMtx, as in other adults.CTRL$@DSpecial considerations forbCTRL$@Ddifferent population groupsCTRL$*D(4/6)CTRL$<DYtdRacial & ethnic groupsDCTRL$FD&BackDCTRL$XDyTopyTCTRL$DDg}r Baseline CHD risk in African CTRL$BDq|Americans, Hispanics, NativeCTRL$@D{wAmericans, Asian & Pacific;CTRL$>Ds)Islanders, & South AsiansCTRL$@D(}3varies somewhat but ATP IIICTRL$DD2=guidelines apply in all groups.CTRL$FD>bNextTCTRL$FD>bNextCTRL$FD>bNexteCTRL$HDFQ Predisposed to abdominal obesityCTRL$<D Pt[and metabolic syndrome.CTRL$@D_zj Many have high CHD risk &CTRL$8D iVtneed intensive tx.CTRL$DD*5factors or advanced subclinicalCTRL$6D4R?atherosclerosis).CTRL$<Dvn Men who smoke & haveCTRL$FD&BackyCTRL$FD>bNextnCTRL$XDyTopyCTRL$@DSpecial considerations forCTRL$@Ddifferent population groupsCTRL$*D(5/6)CTRL$FD&BackhCTRL$FD>bNextlCTRL$XDyTopyCTRL$@DSpecial considerations forCTRL$@Ddifferent population groupsCTRL$*D(6/6)FORM55$$d ,CTRL$6D^Adherence to LDL CTRL$*D(1/4)CTRL$2DLIWPatient focusCTRL$FD&BackCTRL$FD>bNextCTRL$6D[lowering therapyCTRL$BD )ATP III recommends the use ofCTRL$BD (3multidisciplinary methods toCTRL$BD 2=achieve highest levels of CHDCTRL$4D <FGrisk reduction:CTRL$DDXc- simplify medication regimensTCTRL$FDbm- provide explicit instructions &CTRL$0Dl8wcounselingLCTRL$FDv- encourage use of memory promptsCTRL$6D^Adherence to LDL CTRL$6D[lowering therapysCTRL$*D(2/4)CTRL$@Dt)- use systems to reinforceoCTRL$DD (3adherence & maintain pt contactCTRL$@D2=- encourage support networkCTRL$BD<G- reinforce/reward adherenceTCTRL$JDFQ- increase visits for pt's unable to$CTRL$2DP@[achieve goaloCTRL$>DZke- increase access to careCTRL$@Dd{o- encourage self-monitoringCTRL$FD&BackCTRL$FD>bNextCTRL$DD#.Physician/medical office focusrCTRL$*D(3/4)CTRL$6D^Adherence to LDL CTRL$6D[lowering therapyCTRL$DD1<- teach physicians to implementCTRL$4D;FFthe guidelinesQCTRL$FDEP- encourage use of memory promptsCTRL$BDO~Z- designate patient advocateCTRL$FDYd- develop standard treatment planCTRL$@Dc~n- evaluate past performanceCTRL$BDmx- remind pt's of appointmentsCTRL$FD&BackBCTRL$FD>bNextDCTRL$XDyTopytCTRL$FD&BackCTRL$XDyTopyCTRL$6D^Adherence to LDL CTRL$6D[lowering therapyCTRL$*D(4/4)CTRL$BD#.Health delivery system focus$CTRL$HD3>- provide care through lipid clinicCTRL$HD=H- utilize case management by nursesCTRL$:DG`R- deploy telemedicineCTRL$DDQ\- collaborate with pharmacistssCTRL$FD[f- execute critical care pathways&CTRL$2De;pin hospitalsaFORM $$d ,CTRL$DDLW adherence to LDL lowering txCTRL$@D 9|Ddifferent population groupsCTRL$BD*v5 special considerations for CTRL$(D[Rk]LDLCTRL$<D|Management of specificDCTRL$*D(1/9)CTRL$2DGdyslipidemiasCTRL$6D \+LDL >= 190 mg/dLuCTRL$FD/: Usually due to genetic form ofvCTRL$<D9lDhypercholesterolemia. CTRL$BDHS Family testing important toCTRL$BDS}^identify affected relatives.xCTRL$JDbm Often requires statin + bile acid LCTRL$BD +Elevated serum triglyceridesCTRL$FD/: An independent CHD risk factor.CTRL$DD9DMost often seen in persons withCTRL$<DCtNthe metabolic syndrome.CTRL$FD&BackCTRL$FD>bNextCTRL$<D|Management of specificaCTRL$2DGdyslipidemiasCTRL$*D(3/9)CTRL$JDWb Triglyceride (TG) classification:CTRL$JDbmnormal ................... <150 mg/dLCTRL$DDlwborderline .... 150 - 199 mg/dLCTRL$JDvhigh ............... 200 - 499 mg/dLCTRL$FDvery high ......... >= 500 mg/dLCTRL$HDKV In persons with high TG (>=200),CTRL$HDny The goal for non-HDL cholesterolCTRL$HDxcholesterol [total chol - HDL] canhCTRL$FD* be set at 30 mg/dL higher thannCTRL$.D)/4for LDL.oCTRL$FD&BackCTRL$FD>bNextYCTRL$XDyTopyCTRL$<D| Management of specifictCTRL$2D GdyslipidemiasCTRL$*D (5/9)CTRL$DD( For high TG, consider drug txCTRL$FD'2for high risk persons to achieveCTRL$>D1v<non-HDL cholesterol goal.CTRL$HD;FDrug tx can be either intensifyingCTRL$FDEPof LDL-lowering drug, or cautiousCTRL$LDOZaddition of nicotinic acid or fibrate.CTRL$@D_zj For very high TG (>=500),CTRL$DDitinitial aim of tx is to preventCTRL$@Ds{~acute pancreatitis throughCTRL$<D}dtriglyceride lowering.CTRL$FD&BackCTRL$FD>bNextTCTRL$XDyTopyaCTRL$<D| Management of specificCTRL$2D GdyslipidemiasCTRL$*D (6/9)CTRL$BD{' Tx of very high TG includesCTRL$@D 'x2very low fat diet (<= 15 %CTRL$FD 1<of calorie intake), weight loss, CTRL$DD ;Fincreased physical activity, &oCTRL$DD EPusually a triglyceride-loweringCTRL$FD OZdrug (fibrate or nicotinic acid).CTRL$8Dk'Low HDL cholesterolCTRL$FD*5 A strong independent predictoriCTRL$.D4.?of CHD. oCTRL$FD&BackCTRL$FD>bNextkCTRL$XDyTopyCTRL$<D| Management of specificCTRL$2D GdyslipidemiasCTRL$*D (7/9)CTRL$@DPw[ In persons with low HDL, CTRL$:DZ`efirst reach LDL goal.CTRL$HD JU If low HDL is only dyslipidemia, CTRL$HDT_drugs for HDL raising (fibrates orCTRL$HD^inicotinic acid) can be considered;CTRL$DDhshowever usually only in personsCTRL$BDr}}with CHD or risk equivalent.CTRL$FD&BackCTRL$FD>bNextlCTRL$XDyTopybNextnCTRL$DD* For TG 150-499, 1 aim of txCTRL$@D)x4is to reach LDL goal. ThenCTRL$@D3>empahsize weight reductionCTRL$DD=H& increased physical activity.CTRL$DDU`non-HDL cholesterol can be a 2CTRL$>D_ojtarget of tx, after LDL. CTRL$FD&BackCTRL$FD>bNextCTRL$XDyTopyCTRL$<D|Management of specificCTRL$2DGdyslipidemiasCTRL$*D(4/9)CTRL$HD;F LDL & non-HDL goals per category:CTRL$6D`JkCHD & Risk Equiv.CTRL$*DR`ik< 100CTRL$4DR?]Risk category aCTRL$,DuR]non-HDLCTRL$*D`k< 130CTRL$JDU`_____________________________________CTRL$JDdo_____________________________________CTRL$4DoBz2+ Risk FactorsCTRL$*DRoiz< 130CTRL$*Doz< 160CTRL$JDr}_____________________________________CTRL$4D~A0-1 Risk FactorCTRL$*DR~i< 160CTRL$*D~< 190CTRL$0DE;P(in mg/dL)CTRL$JD_____________________________________CTRL$<DBqM Low HDL = <40 mg/dL.CTRL$DDhs Then tx metabolic syndrome, )CTRL$FDr}if present, with weight reductionCTRL$<D|dand physical activity.LCTRL$DD "- If TG 200-499 with low HDL, TCTRL$:D,i7aim to reach non-HDL CTRL$FD>bNextCTRL$FD&BackCTRL$XDyTopyCTRL$<D |Management of specificCTRL$2D GdyslipidemiasCTRL$*D (9/9)CTRL$DD -8 Characterized by high TG, lowCTRL$6D 7UBHDL, & small LDL.CTRL$4DGSpecial issuesCTRL$FD! mgmt of specific dyslipidemiasCTRL$DD (-------------------------------CTRL$>D 1k<------------------------CTRL$BD @K-----------------------------CTRL$DD S^-------------------------------CTRL$BD&CTRL$BD*HCTRL$BDJ[CTRL$FD&Back CTRL$6D6PAcholesterol goal.FORM$$r :yyCTRL$.Dd3>LDL levelCTRL$4DQ;\initiate TLC: CTRL$*D%S5^_ _ _CTRL$\D2+ 10-20 q CTRL$rDNLDL lowering txRaq `qCTRL$4D>Risk category:\CTRL$FD&BackDCTRL$0DB/MLDL goal: CTRL$6D`Kkconsider drug tx:CTRL$2DU`k>= 130 mg/dL CTRL$0D[BM< 130 mg/dLCTRL$2DUQ\>= 130 mg/dLCTRL$HDFQ___________________________________CTRL$HDU`___________________________________CTRL$HDdo___________________________________CTRL$4Dr>}patient's LDL:CTRL$(EA^rqCTRL$*Dur}mg/dLCTRL$2D3=>For category:CTRL$HD7B___________________________________CTRL$D%R8]a'Therapeutic Lifestyle Changes': ATP III's lifestyle approach to cholesterol lowering and CHD risk reduction. BSee info menu for details.BpCTRL$:Dc*(10-year risk 10-20%)CTRL$6DT2+ Risk factors CTRL$4DD10-yr CHD risk:CTRL$(EA^qCTRL$&Dt|%FORM$$ JyyCHDfromFrame CTRL$.Da.9LDL levelCTRL$4DJ;Uinitiate TLC: CTRL$*D&L6W_ _ _CTRL$`DCHDfromFrame q CTRL$DDcn(100-129 mg/dL: drug optional)CTRL$FD&BackCTRL$DNLDL lowering txRa q`dSa q`qCTRL$4D>Risk category:$CTRL$>DCHD & CHD Risk EquivalentCTRL$8D[*(10-year risk >20%)CTRL$2D.=9For category:CTRL$HD2=__________________________________CTRL$0D</GLDL goal: CTRL$0DX<G< 100 mg/dLCTRL$HD@K__________________________________:CTRL$2DRJU>= 100 mg/dL*CTRL$6DXKcconsider drug tx:CTRL$2DRXc>= 130 mg/dL CTRL$HDhs__________________________________RCTRL$4Ds>~patient's LDL:CTRL$(EAXsnCTRL$*Dqs~mg/dLCTRL$HDNY__________________________________TCTRL$D&K8Ve'Therapeutic Lifestyle Changes': ATP III's lifestyle approach to cholesterol lowering and CHD risk reduction. BSee info menu for details.Bp|CTRL$&Dqy%CTRL$(EAXnCTRL$4DD10-yr CHD risk:FORM$J q MENUSFTBG&ILDLCHOSPITALCHMGSCMETHODCFRAMINGHAM CHDLNAGENTOTALCNSYSTOLICNDIETCBILESCNICOTINICCFIBRICCLDLNEatp30000_ATP3T168kXoW,F,G@,FXTABLatp3@nSFTBILDLCHOSPITALCHMGSCMETHODCFRAMINGHAMCHDL NAGE NTOTALC NSYSTOLIC NDIETCBILESCNICOTINICCFIBRICCLDL NIf LDL is 100-129 mg/dL at baseline or on LDL- lowering tx, several therapeutic approaches are available: -Initiate or intensify lifestyle and/or drug tx's to lower LDL. -Emphasize weight reduction & increased physical activity in pt's with the metabolic syndrome. -Delay use or intensification of LDL- lowering tx's & institute tx of other lipid or non-lipid risk factors; consider use of other lipid- modifying drugs (e.g., nicotinic or fibric acid) if pt has high triglyceride or low HDL.vIn persons admitted to the hospital for a major coronary event, LDL should be measured on admission or within 24-hours. This value can be used for treatment decisions. In general, persons hospitalized for a coronary event or procedure should be discharged on drug therapy if the LDL is >=130 mg/dL. If the LDL is 100-129 mg/dL, clinical judgment should be used in deciding whether to initiate drug treatment at discharge, recognizing that LDL levels begin to decline in the first few hours after an event and are significantly decreased by 24-48 hours, and may remain low for many weeks. Thus, the initial LDL level obtained in the hospital may be substantially lower than is usual for the patient. Some authorities hold drug therapy should be initiated whenever a patient hospitalized for a CHD- related illness is found to have an LDL > 100 mg/dL.AGENTS & DAILY DOSES: -lovastatin (20-80mg) -pravastatin (20-40mg) -simvastatin (20-80mg) -fluvastatin (20-80mg) -atorvastatin (10-80mg) -cerivastatin (0.4-0.8mg) ...................................................................... LIPID/LIPOPROTEIN EFFECTS: -LDL decrease 18-55% -HDL increase 5-15% -TG decrease 7-30% ...................................................................... SIDE EFFECTS: -myopathy -increased liver enzymes ...................................................................... CONTRAINDICATIONS -absolute: active or chronic liver disease -relative: concomitant use of certain drugs (e.g., cyclosporine, macrolide antibiotics, various anti-fungals, & cytochrome P-450 inhibitors). Use fibrates & niacin with caution. ...................................................................... CLINICAL TRIAL RESULTS: -reduced major coronary events, CHD deaths, need for coronary procedures, stroke, and total mortality.GThe first step in selection of LDL-lowering therapy is to assess a person's risk status. ATPIII identifies 3 categories of risk that modify the goals and modalities of LDL-lowering therapy: 1. CHD or CHD Risk Equivalents. 2. Multiple (2+) Risk Factors. 3. 0-1 Risk Factor. The category of highest risk consists of CHD and CHD Risk Equivalents. The latter carry a risk for major coronary events equal to that of established CHD, i.e., >20% per 10 years. CHD Risk Equivalents comprise: *other clinical forms of ASCVD (peripheral arterial dz, abdominal aortic aneurysm, and sympto- matic carotid artery dz). * diabetes * multiple risk factors that confer a >20% 10-year risk for CHD (see below). Diabetes counts as a CHD risk equivalent because it usually associates with multiple risk factors; furthermore, persons with diabetes who experience a myocardial infarction have an unusually high death rate either immediately or in the long term, which calls for a more intensive prevention strategy. Assignment of a patient to the second (Multiple Risk Factor) or third (0-1 Risk Factor) categories is performed by first counting the number of risk determinants. These are: * cigarette smoking. * hypertension (BP >140/90 mmHg or on anti-hypertensive medication). * low HDL (<40 mg/dL). * family hx of premature CHD (CHD in male first degree relative <55 years; CHD in female first degree relative <65 years). * age (men >45 years; women >55 years). * Note: HDL >60 mg/dL counts as a "negative" risk factor; its presence removes 1 risk factor from the total count. (LDL is not counted among the risk factors because the purpose of counting those risk factors is to modify the treatment of LDL.) Second, for persons with multiple (2+) risk factors, 10-year risk assessment is carried out with Framingham scoring (see "Framingham risk scoring") to identify individuals whose short-term (10-year) risk warrants consideration of intensive (drug) treatment. Framingham scoring is not necessary when 0-1 risk factor is present because 10-year risk rarely reaches levels for intensive intervention; a very high LDL level in such a person may nevertheless warrant consideration of drug therapy to reduce long-term risk. Persons are assigned to the Multiple (2+) Risk Factor category if they have multiple (2+) risk factors and a 10-year risk for CHD (by Framingham scoring) <=20%. Persons with multiple risk factors in whom the 10-year risk is >20% are assigned to the CHD or CHD Risk Equivalent category. The 0-1 Risk Factor category consists of persons having 0-1 risk factor; with few exceptions, persons in this category have a 10-year risk <10%. In determining the risk category for persons with multiple (2+) risk factors, 10-year risk assessment is carried out with Framingham scoring (see Appendix in the Executive Summary) to identify individuals whose short-term (10-year) risk warrants consideration of intensive (drug) treatment. Estimation of the 10-year CHD risk adds a step to risk assessment beyond risk factor counting, but this step is warranted because it allows better targeting of intensive treatment to people who will benefit from it. When 0-1 risk factor is present, Framingham scoring is not necessary because 10-year risk rarely reaches levels for intensive intervention; a very high LDL level in such a person may nevertheless warrant consideration of drug therapy to reduce long-term risk. Risk factors used in Framingham scoring include: * age. * total cholesterol * HDL. * blood pressure * presence or absence of cigarette smoking. Total cholesterol is used for 10-year risk assessment because of a larger and more robust Framingham database for total than for LDL-cholesterol, but LDL-cholesterol is the primary target of therapy. Framingham scoring divides persons with multiple risk factors into those with 10-year risk for CHD of >20%, 10-20%, and <10%. It should be noted that this two-step sequence can be reversed with essentially the same results. The initial risk assessment in ATP III uses the major risk factors to define the core risk status. Only after the core risk status has been determined should any other risk modifiers be taken into consideration for adjusting the therapeutic approach.- SATURATED FAT: < 7% of total calories - POLYUNSATURATED FAT: up to 10% of total calories - MONOUNSATURATED FAT: up to 20% of total calories - TOTAL FAT: 25-35% of total calories - CARBOHYDRATE: 50-60% of total calories - FIBER: 20-30 grams/day - PROTEIN: approximately 15% of total calories - CHOLESTEROL: < 200 mg/day - TOTAL CALORIES: balance energy intake & expenditure to maintain desirable body weight/prevent weight gain.2AGENTS & DAILY DOSES: -cholestyramine (4-16 g) -colestipol (5-20 g) -colesevelam (2.6-3.8 g) ..................................................................... LIPID/LIPOPROTEIN EFFECTS: -LDL decrease 15-30% -HDL increase 3-5% -TG no change or increase ...................................................................... SIDE EFFECTS: -gastrointestinal distress -constipation -decreased absorption of other drugs ..................................................................... CONTRAINDICATIONS: -absolute: dysbetalipoproteinemia, TG >400 mg/dL -relative: TG > 200 md/dL ...................................................................... CLINICAL TRIAL RESULTS: reduced major coronary events and CHD deaths.AGENTS & DAILY DOSES: -immediate release (1.5-3 g) -extended release (1-2 g) -sustained release (1-2 g) ................................................................... LIPID/LIPOPROTEIN EFFECTS: -LDL decrease 5-25% -HDL increase 15-35% -TG decrease 20-50% ...................................................................... SIDE EFFECTS: -flushing -hyperglycemia -hyperuricemia (gout) -upper GI distress -hepatotoxicity ..................................................................... CONTRAINDICATIONS -absolute: chronic liver dz, severe gout -relative: diabetes, hyperuricemia, peptic ulcer dz ..................................................................... CLINICAL TRIAL RESULTS: reduced major coronary events and possibly total mortality.AGENTS & DAILY DOSES: -gemfibrozil (600 mg BID) -fenofibrate (200 mg) -clofibrate (1000 mg BID) ..................................................................... LIPID/LIPOPROTEIN EFFECTS: -LDL decrease 5-20% (may increase with high TG) -HDL increase 10-20% -TG decrease 20-50% ...................................................................... SIDE EFFECTS: -dyspepsia -gallstones -myopathy ....................................................................... CONTRAINDICATIONS: -absolute: severe renal dz, severe hepatic dz ..................................................................... CLINICAL TRIAL RESULTS: reduced major coronary events.5.2.1SF52RDKcrsr3ptaP ,F,F,FapplSMSEcode^codejcodeIFdatatSTLmtFRMLMBAR$gTbmptFRM4tSTLLtAIBÙtAIB)tFRMĹMBAR1tFRMŌMBAR.Talt tSTLRTalt ƎTalt ƮTalt codeTalt tAINTalt (pref;tverECNVH8>.|xAHPBgNOE&\Ofp`?</BgNOI(H/ NOO:vO `?/ NO[&H \Ogl/ NO!$HHj0/.NOJ@O fD0. j f: jg2=jJGgn`nHxHn FHh/ NOvxO/ NO"JDXOfRCEe~/ NOJ0XOLN^NuSFMC_SetSyncStepEnableState SFBrokerNVH8,.:. AHPBgNOE&\Ofp`?</BgNOI(H/ NOO8vO `\?/ NO[&H \OgJ/ NO!$HHj0/NOJ@O f(j f" jg6*/ NO"/ NOJ0@PO`/ NO"XORCDe/ NOJpXOLxN^NuSFMC_GetSyncStepEnableState SFBrokerNVH vAHPBgNOE(\Ofp`Z/.NOR@6p0/NO$HBg/ NOB'p0// NO'/./ NO/ Bg/BgNO6O,g / NOpXO`pLN^NuSFMC_RunSync SFClientNVH8Jfp`^AzHPBgNOE&\Ofp`H?</BgNOI&HBg/ NO[$H Og/ NO!(HHl/.NO/ NO"O/ NOJpXOLN^NuSFMC_GetDeviceGUID SFServerNVH8zJg,-T+nT$mTp0EJ-g mT?( F?(N1XONR-&m2&Sp+7&mHG mT(@gpv`N(HHx/ / NO&RCpO mTheJDf?<AHPNL\OB' m2 Pp(8//-DNO'|!O vRpgJS@g6S@g6S@g0S@g*S@gS@gS@gS@gQ@g@S@g,S@gS@gS@gRS@gXS@gS@g,S@g\Q@grS@gJ@gS@g~S@gxS@grS@gxS@gfS@g`@ gS@gzS@ghS@gZS@gh@ g`S@gZS@gTS@gNS@gHS@gB@ g^S@g@S@g:S@g@ g~S@gxS@grS@gl[@gtS@gnS@ghS@gb[@g&`z` N TO`NTO`/ N&XO`/ N&XO`/ NXO/NjvXO`/ HnNPO/./.NvPO`/ NXO/NvXO`N0v`zp?NvTO`hp?NvTO`VNvTO`HNTO`S@g U@gS@gS@g$@zgS@g S@g S@g`B-`*@g0 00fe/*AfHPHmNOO `/ NXO` fA>HPHmNOPO`/*HmNOPO`*@gB'/*/*HmNO`</*/*HmNO`rJgAHPHmNOPO`ZAHPHmNOPO`H<<PHm/*/*NO`*A`p j`jB-/ NNXO`?<AHPNL\OHmNO6 C XOlGHm/ NOPO`"0R@?N&H%HHm/ NOO KL N^NuConvertToString&%lu-2147483648TrueFalseInterp.cNV/ /N$H/ NB*JXOf *WDHH%@&$_N^NuOp_IsEmptyNV/ / $n&n Hx/ / NO& O f/+N&%HXOf` f/+N,%HXOf` J$_&_N^NuStackItemConstructCloneNV/ $n f /*NXO` fJg /*NXO$_N^NuStackItemDestructCloneNV/ $n/ HnN$ POfp`DHnN-n-nHnNt-n-n-n-n/ HnN Ofp`HnNb-n-nHnN(/./.Hnt NO/./././.t%NOJO$g/./.B/<t(NOJOg,/</`Z/+/+/*/*HnNO`L/+/+/*/*HnNO`./+/+/*/*HnNO`?<QAHPNL\O/./.N$PO`p@P @b@0;N 0Tx/+/+/*/*NJ@WDO`R/+/+/*/*NJ@^DO`./+/+/*/*NJ@\DO` /+/+/*/*NJ@]DO`/+/+/*/*NJ@_DO`/+/+/*/*NJ@VDO`BBp@@g S@g$W@g>`Z/+/+/*/*HnNO`L/+/+/*/*HnNO`./+/+/*/*HnNO`?<tAlHPNL\O/./.N^PO` Efz/+/+/*/*Hnt5NO .Ofz` .gzp@P @b^@0;N $<0HJEWD`JEVD`JE^D`tJE]D`hJE\D`\JE_D`P?<AHPNL\O`JEWD`BJEVD`8JE^D`.JE]D`$JE\D`JE_D`?<AHPNL\O/ Nߞ/ NߘPOp/NXOLxN^NuOp_CmpBinaryPInterp.cInterp.cInterp.cInterp.cInterp.cInterp.cInterp.cInterp.cNVH8N(HN&H/ N`&/ NX(p.PO@Bg`8/NO=@/NOn:0R@?N$H// NO// NOO`?<ALHPNL\O/ Nޞ/ Nޘ POf?< A4HPNL\O/ NNXOL8N^NuOp_StrBinaryInterp.cInterp.cNV/ Nߢ$H f *WDHH%@`/ N *F%@XO$_N^NuOp_NotNV/ N\$H f `/ N* *D%@XO$_N^NuOp_NegNV/N߀JVDg .bg Jf .af 0n A `p&N^NuOp_JumpCondNV/ m2 Pp0(d m2А$@p0.r22Ҋ AHPN@XO$_N^NuOp_CallNVH0.-!H-!HRA@l?< aAHPNL\O n g?. N&H TOg$k f ?. N$HTOHS@H/Nފ// N-!O gFHR@-!H@g6HRC`p mDAHPN܈RCXO-!H@oD!/-N@XOL N^NuOp_ExecExt Interp.cNVH .v gBgN޾$H/ NO6\Op @b@0;N ft0C/N\XO`Nݶ8Cc8 fp0B2/ N&XO/NXO`A0p0HPN&XO/NXO`p/NXO`tN\?<N$HB*/ NP\O`RN:8N4:Cc80ECc:D0Er2B2p0HrN&XO/N XO`?< A*HPNL\O g/ NXOL8N^NuOp_StrOp Interp.cNVH8Nܶ6Nܰ8BgNp$HBgNh(H/ NO:/ NO<EO c60DEc8CDf p0// p0A/NO&* O `d>FD0R@?N*TOf?< 4A|HPNL\O&Ep0// / NO&p0/ / NOp0p0Ap0Hp/ NOO/N XOg/ NXO/ NXOLN^NuOp_MidAssign Interp.cNVH $nvp @br@0;Nh 2DVhHj*N,&\O`XHj*N.&\O`FHj*Nn&\O`4Hj*N&\O`"Hj*N &\O`?< sA&HPNL\O TLN^NuOp_MemberRef Interp.cNVH $nvpU@gDS@g S@g*S@g`HHj*N (&\O`FHj*N &\O`4Hj*N (&\O`"Hj*Nh&\O`?< A&HPNL\O TLN^NuOp_PropAssign Interp.cNVH0&nv?<N$Hp5@BjBjpTO_@g`p+5@v`?< A HPNL\O RL N^NuPushRef Interp.cNVH v=n-n nR nJgnEE`d nH@Fg,W@g@ g`6/NVA$HXO`6/NA$HXO`&/*/*NA$HPO`?< AxHPNL\OR nJfHnNHXO@Fg$W@g@ gW@g&`BgN&TO`N&`?< A.HPNL\O LN^NuMemberAccessInterp.cInterp.cNV/ Jmf@EEB'HxHnNO'=n4 5n 5nHxHnHmNO&O$_N^NuPostDeferredEventNV/ /6-EEBm0@g`*?*?N$\O`?< [A&HPNL\O&$_N^NuExecDeferredEvent Interp.cNV/ /JNf\?<N"+HNTOf?< nAHPNL\OB'HxHnNO'-|CALL=|HxHnB/-NNOvBmLBmRO`0 m2 Pp(9mRdB'N4AHP?< AHPNOO B'HxHnNO'-|SREC=mL-!HR@n @n p.v.@PCJmLO g mN0-LChcV0(@?/-NN(+HN\Of?< AHHPNL\OHx/-NHnNO&nHxHnB/-NNOvOp0-LЭN$@p*r*@PAmL`;|LvHxHnp0-L//-NNOvJ.Og4p.//-DpPr2-LҀ//-NNOvp.@OJ.gB$m2$Rp*7$mHEp.// pPr2-LҀ//-NNOvORmR&$_N^NuPushState8Interp.cMax call depth exceeded!Interp.cInterp.cNVH0JNg mLdB'N4AHP?< AHPNOO p0-LЭN$@vJ*g*p*/pA//-DNO&p*@O *S@!J*g8&m2&Sp+7&mHGp*/pA// NO&O ;jLSmRL N^NuPopState"Call buffer underflow!Interp.cNVBg/./././. /.tNON^NuFloatAddNVBg/./././. /.tNON^NuFloatSubNV/./././. /.t4NON^NuFloatMulNV/./././. /.t6NON^NuFloatDivNV/././. /.t%NON^NuFloatEqNV/././. /.t)NON^NuFloatGtNV/././. /.t*NON^NuFloatGeNVH8.z<<8$H \Of?<AHPNL\Op @b@0;N~,xV~VV6DD/ NJr2XO/NxXO`&H mV8(Nм>Nж6JF\Og Cff6`6* CgxFc>Fe6C=GGdSnHn??*?-RNfO fOgp`p/ NJXOgSnNќ8p0./N?Np/NTO `HkN6 mV P?( N>&Hp\O@gS@g,`P<??/ N\ON?*?-RNO `&B'??/ N\ON?*?-RNO f,B'?<N$H TOf?<ADHPNL\ON06/ ND8DXOe6C5C L8N^NuTablePropAssign ObjTable.cNVH $n8. BB?/ Nr6\O0@DgU@gQ@g W@gW@g`|0.Q@g [@g*S@gJ`jHn??*?-RN~6O gPBB`FHn??*?-RN6O g,BB`"Hn??*?-RN6O gBB/./.NܒPOLN^NuDoTableOpNVH v n HhN8p.XOS@g`2/. NXO?N>$H TOf?<0A0HPNL\O?/ N\O LN^NuFieldMemberRef ObjField.cNVH v n HhN8p.XOS@g`2/. NXO?N>$H TOf?<FA0HPNL\O?/ N>\O LN^NuFieldPropAssign ObjField.cNVH $n:. vBx8*JZg$ mZfp0(f?/-ZN-H\O`$Hn???*?-RNxJ@O fv`BJg. n d np` nHhNXOJ@fN`JJg6 n d np` nHhNXOJ@g?/ NJ\Og nJf` n d nR` nV$Hp@?gY@gS@gU@gRS@g[@gfU@gW@g"U@gS@g`/ NXO/NZXO`/ HnNPO/./.NؘPO`t/ HnNPO/./.NPO`V TWDHH/NXO`>/ N&$H/ NbPO`*/.HnNvHnN&$H/ N@O`/.HnNHnN&$H/ NO` n d np` nHhNXOJ@gp`p8 n d np` nHhNXODfNT` n d np` nHhNXOJ@gp`p8 n d np` nHhNXO: npHp0D?N:\O`A@HPNXO` A4HPNXOJgJg /.NXOL8N^NuPushFieldNVH8(n:. ʗvx8,NtJf NBn`?/ N G\OfvNL f8N&H k=P$kBp0./ kHhA/NO&RnO `vBgN8&H/ NOR@=@R@?N$H POg Bp0.// A/NO&RnO `Bn/ NXO`"BgN&HHn?/ / Nt$H/ NOJZg* mZf"p0(f?./ ?/-ZNO`*?/ N&H \Og?./ ?/ N/ NO g/ NXOL8N^NuFieldAssignNV/ / &n Hn/ ?<< HnN$H n0((n@d5@ S"S0)h@ Sh4 S5h5| S"S0)hR@5@* *@ S ( Of* p0.$_&_N^NuFormAllocScrollbarNV/. /.NN^NuFormDestroyScrollbarNV/HnHnHn/. NO0.nOc 6.n`Jng6.`v0.@??Bg?./.NOO &N^NuUpdateScrollbarNVH0$n6. / N&HB'/ N$HJCO l/ NO8B'0D@?/ NOLJDO gt$k f?<AHPNL\O`ZHnHnHnHn/ NO0D@@Ocn`n?.?.?.?./ NOO `JCo<?/ NOLPOL N^NuProcessScrollbar DynScroll.cNVH /.NOx6 @XOg?N: @TOg 6- Cf?<N$HBTO`?<N$HBAHP/ NOp0/HnNOHnNO8vO`AHP/ NOSCPODnHn/ NOAjHP/ NOp0/HnNOHnNO8vO`ABHP/ NOSCPODnHn/ NOPO JL8N^NuFormGetFocus %F0.C0NV//x/. N6p.XO @ b@0;N2\`jdHpt/<??<NPO` mVp0( /NbXO` mVp0(/NLXO`pv`v `6<@` 6< `v`vJ-eg B'?NXO`DB'?N$HNš6 TOg,/ ND@XOd J-ef ?N*TO`<<?N\O LN^NuFormPropAssignNV*H8.xp @b@0;N<<~ 08.^dtDrtBgN¬$HJTOf / NXO`/ NrXO/N XO/ NXO`BgNt$HBgNl&HBgNd(HBgN\&BgNT*/// / / NFHO/N / N/ N/ N/N/NO"`*?< N $HN<6TOlv</ N2/ N.O `N dv` cvN^TO`|N-@N=@N=@ @@c=|@JgJngB'HnBNO3O `N&/NXO/NOXO`nHnHnHnNON¤60n/N ?NNŽ60n/N?Np./NΦO`Nd6p0-l/N?NNL6p0-n/NͰ?NN46p0-p/N͘?NШO`HnNO/NOe?.NOcTO/N͘O `BgN$H/ HnjNpHnkN8XO/Nn/ NO`xN&/N>$H/ HnJNvHnJN&XO/N|/ NO`BNO/N XO`2BgN$H/ HnN|A gJ.f` .d AA`AAHPNJXO/N/ NO`N&/NP$H/ Hn*NHn*N&XO/N/ NO`NO/ǸXO` 0feNOr2/NbXO`tHxdNTXO`fN+@/-N+@XO`LBBB`HPNL\O L8N^NuAppMemberRef$ObjApp.cNVH8z/. NXO?N$H TOf /-:NRXO f?</A HPNL\Op. @ b@0;N"~j:R$/ NXO`/ N@rXO/NʸXO`/ N?rXO/NʠXO`|/ NA:rXO/NʈXO`d/ NAXO/N XO`PB'/ N\O`B R hg R h f,/* mV/(NPO` R h f N6B'/ N&H \OgJClp`pJCm0`0D@?/ NOL 0fPOe(j g/ / NPO` R hg R h fB'/ N&H \OgHnHn/ NO:NX6p0./Nȼ?NN@6p0./NȤ?N˴O`< R hg R h f(B'/ N&HN6N8 \Og ??/ NOBPO L8N^NuControlMemberRef ObjCtrl.cNVH0v/. NXO?N$H TOf?<AHPNL\Op. @bn@0;NdddJ*:/ NNXO`JN2/ NA<\O`:N"/ N@>\O`*N/ NC>\O`BgN&H/ / NC/ NO L N^NuControlPropAssign ObjCtrl.cNVH8$n/ N:&H/ Nȶ(HN<&H R hPOgHn/ N6PO`2 Rp0(В @?N>( Rp0(В @?(/Nr6PO0@?gJY@gFS@gBU@gS@g:[@gU@gW@g U@gS@g&`$/ NXO` TWD/ N:p'@XOLN^NuPushCtrlNVH8ENt&HHn/.NPO@?gY@gS@gU@gS@g[@gPU@gW@gnU@gjS@g`Jg fJ+g f kJfB`?<B/ NVN\/ gJf` dA`A/NO`zJg fJ+g f kJfB`V?<B/ NVHnNXXO/./. gJf` dA`A/NO`Jg fJ+g f kJfB`?<B/ NVHnN XO/./. gJf` dA`A/NO`N@?<Hn/ NVO `BgN&H/ NOR@XO?/ NP(H POf?<AHPNL\O$L/ NXO`DBgN&H/ / N|/ NO`(BgN&H/ / Np/ NO` N/NXO/ /.NP POg/ NXOLN^NuCtrlAssign ObjCtrl.cNVH8&n =| Sp0(Г(@Hn/ ?<<HnN$H n0((n@d4 S5h S5h*B*p S Og|`" S he 0fdp` S0(@ S ( f*B Bg/ NOR@XO?HnN$H/ / NOp0.OLN^NuFormAllocLabelNVH8(n 6,HnBg/PO`r/ / N PO`f/ / NUfPO`Z/ / NVPO`N/ / NV\PO`B/ / NAPO`6/ / NRzPO`*Jg jp BHx/*N/ / NOp%@RDEe mV/(NPpXOL 8N^NuFormDestroyControls CommCtl.cNVB'<N N^NuLoadFormWithCurrentRowNVH . JZg /-ZNXO mV P?( N>$H TOgJZg?<AHPNL\OJf mV?(/ N+HZ\O mV/(NOxr2(JZXOgNN P0fe J`f|_ mV P:(6C`p$mVEpg R0( @b@0;N2$\$N@@j2x/-Z/ N*PO`b/-Z/ N:ZPO`T/-Z/ N(PO`F/-Z/ NPO`8/-Z/ NlPO`*/-Z/ NKrPO` mVp0(/Hx/*NO SCJCl8B-_J`gNOB`/ mV/(NJPOf4|eJ.g( mV hgBBHxHxN?<NOJf|eBNXOLxN^NuLoadFormWithCurrentRowEx CommCtl.cNVH vNfv` mV P?( N>$H TOg mV P0(@g mV hgJ-egJZg P8(v`p$mVEpg R ( f R0( @b@0;Nxxx2xx$xx$x@@Nxxx\/-Z/ NPO`F/-Z/ N9&PO`8/-Z/ N'HPO`*/-Z/ NJPO` mVp0(/Hx/*NO RCDeD/-ZNXOJgJZg /-ZNXOLN^NuCommitFormToCurrentRowNV/NSf B'B'NnXO&N^NuCommitFormToCurrentRowV41NVH0&n$n S0( @b@0;N0DDP0Hx/ / NO `xBg<?/ / N6O `d/ / N%\PO`X g@Jg< dp` HjNXOJ@gp`p6 dp` HjNXOCf/ NIHx/ NEO L N^NuLoadControlNV/ / &n S0( @bb@0;NXXX*XXXXX6BN*/ N"$HXO`./ N58$HXO`"/ NQJ$HXO`/ N&$HXO` / NI$HXO f?<N$HBTO J$_&_N^NuGetControlDataCopyNVH0$n&n vC R0(W@gTO/Nr6O `D/ Rp0(В @?( Rp0(В @?N>TO/Nr6O ` vL`vN gBS C?fvC0L N^NuGetControlDataTypeNVH . mV P?( N>$H TOg@ mV P8(v`.p$mVEpg R0(@ g` / N\ORCDeL8N^NuFormTableSizeChangedNotifyNVH0v?<NTOgBBHxHxNOg mV P:(x`p$mVEpg R (  gX/ N&H XOg / NOJ@XOf2v/-N R hXOg R h f/* mV/(NPO g/ NXO mV P?( N>&HJTOg g R hf / / NPORDEdJfJL 8N^NuFormValidateNV/ / &n Hn/ ?< <HnN$H n0((n@d4 S5h S5h S"S0)hR@5@ S"S0)hR@5@5m" B Bj5|BjB* S ( Of* p0.$_&_N^NuFormAllocListNVH0&n 6+?/.NO$H?/ Sp0(Г @?NHm/ NOpOL N^NuFormInitListNV n P h g?<A4HPNL\O/.N/. /.NN^NuFormDestroyList DynList.cNVH8&n(n 8< S h g?<APHPNL\O?+ mV/(NO$H mV/(NOx: O f?<A"HPNL\O?+ mV/(NJ\Og P0feJ`f B'NO+H`TO g8,/ NO?.TOg\J-^fT0.kdH D0(U@=@:?./ N=@|\O` &Rp0+Вr &@G??./N&POg kgHn?/N@?+?+?+?../N2-H?+N>&Of?<AHPNL\OJg( R(?+/Hn/.Nb(H/.NO`6?<N(HAHP/ NOO ` R(?/Hn/Nb(HO f?<AhHPNL\O?./NvHn R he 0fdp` R0(N6+nO d0`0.60@=@HnHnHn/ NOm0+ @Of D?(??./ NO O `" D?(0Cn@??./ NO O p R gB Rp0(В @0R@hd, D"D0)h?0C@??(0C@?NOPO/ NnCRFXOJng Rp0(В @heLN^NuListDrawCallback"DynList.cDynList.c???DynList.cNV/ </.N$HB'<?. /* N\O?NJO fJZg/-Z/ NXO/NZPO$_N^NuProcessListsNV/v0. gS@g&S@gS@g `/.N n( vXO`v`v&N^NuBitmapGadgetHandlerNV/ / &n Hn/ ?<< HnN$H4d**  S5h S5h S"S0)hR@5@ S"S0)hR@5@ S ( Of **J-kg *@Bp0.$_&_N^NuFormAllocBitmapNVH8&n$n 6*?/ NO(HJ-k\OgHm?/ NOO Rp0(В/?/ NOpO LN^NuFormInitBitmapNV/. mV/(NPO? mV/(NO @d\Og?<A.HPNL\O/. /.NN^NuFormDestroyBitmap DynBmp.cNVH8$n(n / NO8vXO`?/ NO \Oft?/ NO&H/ / NPO?/ NO @dO fN?/ NJ\Og@ g4Hn/ / NPO?/ NOHn/ HnNOJnOgJng/ N&XORCDevLN^NuFormDrawBitmapsNV/ //. mV/(N6? mV/(NO\O?N P hO ftHn? mV/(NO? mV/(NO$H Odp` HjNXOJ@gp`p6Hn dp` HjNXOC?pHrN"O &$_N^NuDrawBitmapGadgetNVH8(nB|xB~ n SFRLg$g0`40. Y@=@zBʗvJngR@?N*p0./ nHh/NO&p0. EB0-E?<:/.NO$H Og0BR?<:/ NO&H \OgBR?<:/ NO&\Og CBR gJg gzJgv=mTHnHxB'AHP/ N-@OgP?</.?.NOI,POg:/NO=@Hx/ HnNO&?./.NO`(Og/NO!-H.XO/NXO` nX.JgP P0feNO<NOTOHnNO/ NO?,?/NO&HnNO P0fOeNO`|0,U@?0,U@?0,R@?0R@?HnNOHn?<NO0.n?0.n??.?.NO0.n?0.S@??.0.nS@?NOO"Jg/NO"XOJg/NOaXOJg/NOJXOLN^NuDrawSFRL.PDBNVH8&nJ f?<AHPNL\O S hg S?(/. N$H \OgxpI< / N&Hn?+ mV/(NO OgJ dp` HjNXOJ@gp`p6Hn dp` HjNXOC?/ NO LN^NuRenderBitmap DynBmp.cNVH8$n(n R hg?<AHPNL\O R hg R?(/ N&H \OgBp" €g:/ / N\JPOg?<AHPNL\O/ N&/ R?(/-ZNO< / N&HHn?* mV/(NOBgHnNO Og / / N^POLN^NuLoadBitmapFieldFromCachedRecordDynBmp.cDynBmp.cNVH8&n vHn/ ?<(B'HnN$H n0((n@d4 S5h S5h S"S0)hR@5@ S"S0)hR@5@5m$ B*&p S Og|&`" S he 0fdp` S0(@&Hn*&N8j\Oo5D mV P?( N>(H TOg4 S?(/ N D\Ofv ` Tfv ` S?(/ N6\Op S f2JCg5C`8 S ( g0j @5@`5|`JCg5C`5| S ( f * * S ( g* p S g *? *@ p S g$* 0fep S g * _jp@ S g * * p S g* p S g* * g2/ /.N6 mV-h CPOg p0'@` * Bp0.LN^NuFormAllocFieldNVH0$n 6*?/.NO&HJ\Og.?*/.NO%HHn/ NOO.Hn/ NOPOBgHx/ N4pO L N^NuFormInitFieldNVH8(n$n gJg/ /*NʤBPO/ NOS&H XOg/ NO7XO/ / NPOLN^NuFormDestroyFieldNVH8(n(.B'/ ` N$H \Of?<wAHP` NL\OJ gxJf mV P?( ` N>(TOHn T?(/` N/ NO@/ NOZ:?Hx?./. ` Nn&HO"Bg/ / HzHzNuJO g/ /,HzHzɔNuPO g/ ` NXOL8N^NuLoadFieldControl DynField.cNVH8$n(n R hg R h g?<A^HPNL\O R hg& R?(/ N&H g T`HP/ / NbOLN^NuLoadFieldFromCachedRecord DynField.cNVH8$n&. R hg R h g?<AHPNL\O R hgbB'/ N&H/ NO9(H O f?<ApHPNL\OHn R?( C// Nt&H?./ R?(/N Og/ NXOLN^NuSaveFieldToCachedRecordDynField.cDynField.cNVH8$n*. 6./ NOZ8Hn/ NOO|./ NODJOfA*JCf /NO6XODc6RC/ NOS&H XOfPp0/NO&H XOf  0fe$AHPAHPAHPNON?NOeO`X/-N@XO`JB/ NOX/ NOJ@O g?<yA^HPNL\Op0// NO3J@POg<  0fe$ABHPA>HPALHPNON?NOeO`/-N@XO`/ NO!(H XOf<  0fe$AHPA HPAHPNON?NOeO`/-N@XO`0@r2/// NO&0@r2B4/ NO" P0fOeJ`f B'NO+H`TO/ / NOX</ NO=/ NO6/ NO5J`OgJ-_fNOB`Jg/ NOCXOLxN^NuSetFieldTextVSetFieldText (1): DynField.cSetFieldText (2): SetFieldText (3): NV/ / B'/.N&H/ NO9$H O fE>/ NOR@XO?N&H/ / NO KO $_&_N^NuFieldGetDataCopyNV/ ?.` N $H TOf?<AlHP` NL\O`> R h f4Jg.B'/ ` N\O//*HzHzĖNuPO$_N^NuFieldChanged DynField.cNVH8(nx T hg?<ADHPNL\O T:(?/. Nz&H \Og?/. N N\Og Qg Fg Dg p b/ N$H XOg/ NOJ@XOgp@DgHU@gQ@gW@g U@gS@gR`l+# fv+!/ HnN JO fHx/-N@XO`:/ HnNpJPOf*x/-N@XO`/ HnN|JPOf x/-N@XOJf/, mV/(NPO g/ NXO/ NXOL8N^NuValidateField DynField.cNVH8(nE/ / NOO/ N$H m2 P h"$O dp R gp`pH` Rp0(В @p0(&.gJgpf\ mV P?( N>&H R8( TOg>?/ N ?\Og,p@DgU@gQ@g[@gS@g` v`v` v`v`vpf/ NL&H/ HnNpJO gdJ.g^A gJ.f` .d AA`AA$HHjNO=@B*HjNO=@B*/ NO=@O `NO&Hn/NOPO/ NAHPHnHnHnNOZJOg?.?.?.HnNDHnHnNvHnNOXO?Hn/ NbBNO `pf./ NJ&Hvv XOgDJf@NO&Hn/NOHn-B..NOhHnNOXO?Hn/ NO`R/ HnN|JPOg6A gJ.f` .d AA`AAHPNJ&XOHn/NOPO g/ NXO 0feJAHPHnHnNOOO gJHn-B..NOhHnNOXO?Hn/ NJO` 0fe <NOTO`NOBNXO`Vpf$ 0fe <NOTO`NOBNXO`,.gJl"f<B'B'NO\O<NOBN\OLN^NuProcessFieldEnterSelect DateSelect a new timeNVH8&n Hn/ ?<<HnN$H n0((n@d4B S5h S5h S"S0)hR@5@ S"S0)hR@5@5m&B*B*B* S hOe 0fdp` S0(@ S&( f* g* S0(W@g[@gW@gS@g` m2 P h$d f * g|`pg|`B*RjRjWjWjpf& f**`**`*(Sp0,Г(@T`t f*f*|`|RjRjWjWj g **(Sp0,Г(@\ Sp0(Г @h`|B Bg fp`/ NOXOR@?HnN$HB POg / / NOPOp0.LN^NuFormAllocCtrlObjNVH8$n 6*?/.NO(H R0(\OW@g,[@g W@gS@g`&Rp0+В&@T`&Rp0+В&@\Hx/ NO/ / NjpOLN^NuFormInitCtrlObjNV/ /.NO$H XOg/ NXO/. /.NPO$_N^NuFormDestroyCtrlObjNVH8(n(. fA"(/NOR@6/ NO POf2p0/NO$H XOfHxHxHxNON?NOeO`/ NOXO/NO$H XOf?<|AHPNL\O/ NOS@XOg?<}AHPNL\O/ NO"p0// NO3J@O g"HxHxHxNON?NOe/ NO!O`>/ NO!&H XOf?<AZHPNL\O// NO/ NO/ / NO/ NO OLN^NuSetCtrlObjText DynCtrl.cDynCtrl.cDynCtrl.cNV/. </.N\O//.NN^NuLoadCtrlObjControlNV/ / $n R h g R h g?<AVHPNL\O R hg R?(/. N&H/ / NvO$_&_N^NuLoadCtrlObjFromCachedRecord DynCtrl.cNVH8$n(. Gv R h g R h g?<A HPNL\O R hg</ N(H/ / Nfr2-A R h Of` g R?( D/N N\OfGv`^ Qf/.HnNGvPO`B  0feAxHPAtHPAHPBgNOeO`.AHP?<AHPNOO `?/ R?(/NO LN^NuSaveCtrlObjToCachedRecord|DynCtrl.cRadio buttons must be linked to INTEGER columns.Radio buttons must be linked to INTEGER columns.DynCtrl.cNVH8(n T h g?<MAHPNL\O?<N&H TOf?<RAHPNL\OB'Hx/ NO'B mV P6($mVEO `fpgX R h fN Rp0(В @"Tp0)Д"@0Pf0</ N*// NZ8 @Ogp0// NOPO` SCpJCf KL8N^NuRadioGetDataCopyDynCtrl.cDynCtrl.cNV/ /$n/. NO R h XOf JgvT`vF`Jg Rp0(В @6(`6<0&$_N^NuGetCtrlObjStateNVH8(n$nv g dp` HjNXO8g gJf` dA`A&H g T h g Dfp@Tg[@g @g[@g`Tv`P Df / N:XO`( Df/ HnN:.PO`?<AJHPNL\O Tp0(Д @hWDp?/. NO\OL8N^NuSetCtrlObjState DynCtrl.cNVH0&nv</ N$H \Og S0( @bx@0;NnnnL^^0^^0^b0/ NOJWDXO`>Hn/ NOOp .WDPO`"/ NOJWDXO`v` + WDL N^NuGetCtrlObjReadonlyNVH0$nv</ N&H \Og R0( @b@0;N^t4x4Hx4?* mV/(N\O`XHn/ NOO. PO`D?* mV/(N\O`.?* mV/(N\O`v`?* mV/(N\OL N^NuGetCtrlObjVisibleNVH0&nv</ N$H \Og& S0(]@g W@g[@g`Hn/ NOO. POL N^NuGetCtrlObjUnderlineNVH8(nE</ N&H \Ogp T0( @ bd@0;NZZZ&JZZZZ/ NO$HXO`46,?NOs/NO\O?NOs/NO$H\O` mV/(NO$HXO/ N&XOLN^NuGetCtrlObjCaptionNVH0&n. </ N$H \Og S0( @b@0;N2FFzFWDH/ NO\O`bWDH/ NO\O`NHn/ NOOJPOgp`p ..Hn/ NOPPO`Jgp`p+ + L N^NuSetCtrlObjReadonlyNVH0$n. </ N&H \Og R0( @b@0;N,,^,/ N\O`Jg</ NO\/ NO5O `/ NO6B'/ NO\O `nJg@/ mV/(NPO? mV/(NO P0f\Od+ /-Z/ NPO`*/ NO?* mV/(NO P0fO d+ `Jg?* mV/(NO\O`?* mV/(NO\O`Jgd/ mV/(NPO? mV/(NO R h\Of/ NJZXOg/-Z/ NPO`|/ N>JZXOgn/-Z/ N$PO``/ mV/(NPO? mV/(NO R=h R=h R"R0)hR@=@ R"R0)hR@=@BgHnNOO L N^NuSetCtrlObjVisibleNV/ </.N$H \OgZ n P0(]@g W@g[@g`BHn/ NOOJ. POgp`p.?.Hn/ NOP/ NO6/ NO5O$_N^NuSetCtrlObjUnderlineNVH8&n(n </ N$H \Og S0( @ b@0;N(z/ / NPO`& ?+ mV/(Nr:\Og?+ mV/(NO\OHnBg/&H TOgx Rp0(В @?(?*/ N(H POf?<AHPNL\O`D R( Rp0(В @?(/ Hx/ Nb&?*/ Nҙ// N`/NO"` P0fe 0fe Hx/ N6POLN^NuUpdateDropListTextDynDrop.cDynDrop.cNV/ / &n S ( f</ N$H/. / NDO`B'/ N$HBg/. / NO$_&_N^NuSetTriggerTextNVH8$n Rp0(В @?N>&H TOg^ R( g Rp0(В @0(` Rp0(В @0(6??*/ N(POg?/ Hx/N\(H?*/ NO LLN^NuDropListGetDataCopyNVH0$nJ gV Rp0(В @?N>&H TOg&TOg Rp0(В @?(?*/N&H POgHn Rp0(В @?(/N R?( F/NOg?./ N (H&LO dp` HkNXO8? gJf` dA`A/ R?(/N?*/NO g/ NXOLxN^NuSaveDropListToCachedRecord DynDrop.cNV/v/.N8JXOg/. mV/(NvPO&N^NuProcessDropListsNVH0$nx R hg?<?AHPNL\O Rp0(В @>( Rp0(В @p0(H@=@ Rp0(В @"Rp0)В"@0) h=@ Rv6(֒ C"Rv6)֒"C6) hNOcB'NOdBgNOh0C"?B'??.?.? mV/(NO=@ mV/(NO}n@d<PO? mVHhNO.NOd? mV/(NO6? mV/(NO&H/ ?* Rp0(В @?( Rp0(В @?N/ NO: EO2g?/ N5@x\O/ N S0fXOb Pfd? mVHhNOE\O`? mV/(NO\OL N^NuPopUpDropList DynDrop.cNV/ /v0. gS@g:S@gS@g4`2/.NPvXO`$$n Rf?*?*NSWDXO`v&$_N^NuInkGadgetHandlerNV/ / &n Hn/ ?<< HnN$H4e** J-kOg *@B S0(R@5@ S0(R@5@ S"S0)h@5@ S"S0)h@5@ S ( f ** S ( g*7j p0.$_&_N^NuFormAllocInkFieldNV/ n 6(J-kgHm$?/.NOO p&N^NuFormInitInkFieldNV/. mV/(NPO? mV/(NO @e\Og?<A0HPNL\O/. /.NN^NuFormDestroyInkField DynInk.cNVH0$n/ NO8vXO`@?/ NO \Of.?/ NO&H/ / NPO?/ NO @eO f/ N&XORCDeL N^NuFormDrawInkFieldsNV/.NXO?( mV/(NJ\Og.k Fm" Fn Gm God`Sf 0.kgTj e/ /Nn(H POg>pE E Ph E P0(nJ.gDp05p05Rj LLN^NuRecordInkPoint DynInk.cNVH0$n pG kdN6+C Cc6<8LD?/ N$H \Og$pG0R@?A/N7C \O J``L N^NuGrowInkRecordNVH0&n g\pE INKfN6*KC?/ N&H \Of?<"ALHPNL\OpE0@?A/N5j \O KL N^NuMinimizeInkRecord DynInk.cNVH8$nJ f?<>AJHPNL\O R hg" R?(/. N(H \Og pG dp` HlNXOJ@gp`p6 dp` HlNXOCg< / N(H INK\Og<* R0(T@? R0(V@?/-NO@XO? mHhNO O `rv`hx883HD Rhp0 R:(sp003@f. Rhd& Rhd Rhd Rhd????NOPO<>RCkeLN^NuRenderInk DynInk.cNV/ $n< / ` N-HHn?* mV/(NOBgHnNOHn mV/(HzHz Nu?* mV/(` NJO$g6Hn?<NOJ \Og /. / NPOHnHzHzNuXO$_N^NuLoadInkControlNVH8$n6. (n8.je?<AdHPNL\Op0 r dp0 rp`p0 rHhNXOJ@gp`p:p0 r dp0 rp`p0 rHhNXOE@f.JDgp0// p0 rpA/NOJ@O g/ p0/2N\JPOgp0/2NXOp0X?N&H0R@?A/NJDPOg6 gp0// pA/NO&O `B'p0/pA/NO'O p0%| KL8N^NuSetCachedInkField DynInk.cNVH8$n&. R h g?<AHPNL\O R hg` R?(/N&H \OgBp" €g:// N\JPOg?<$AbHPNL\O/ N(H/ R?(/-ZNO// NPOLN^NuLoadInkFieldFromCachedRecordDynInk.cDynInk.cNV/ $n0j_@=@=j=|=|BgHnNOHn?<NO?<HnNOHn?<NOO$_N^NuDrawEraseButtonNV n P h g?<QA,HPNL\ON^NuSaveInkFieldToCachedRecord DynInk.cNV/ $n R h g?<bAHHPNL\OJZg R hgBgB R?(/-ZNO $_N^NuClearInkRecord DynInk.cNVH8(nGJZgj T hg` T?(/-Z` N$H \Og>pI dp`Hj` NXOJ@g INKf JlgGJ/ NOR@XO?` N$H/ / NO JO LN^NuInkGetDataCopyINK:NVH8$n f?<FAHP` NL\O/ NOr/ NOp?<D` N$HB'HxD/ NO'B?</&H TOgf R hgZ R?(/-Z` N&H \Og6 dp`Hk` NXOJ@g p R fNO(Hn/NO Rp0(В @0POJ@g S@g0S@g(`N?.?.?.Hn` NDO `86.??.?.Hn` NVO `AHPHnNOPO .dp.`Hn` NXO6?A gJ.f` .d AA`AA/ R?(/-Z` NO L N^NuExecAutoStampDynStamp.cDynStamp.cnrrorNV/. /.NиN^NuFormAllocButtonNV/. /.NN^NuFormInitButtonNV n P hg?<4A.HPNL\O/. /.N*N^NuFormDestroyButton DynBtn.cNV/. /.NN^NuFormAllocRadioNV/. /.NN^NuFormAllocCheckBoxNV/ n 6(?/.NO-Hp\O&N^NuFormInitCheckBoxNV/ n 6(?/.NO-Hp\O&N^NuFormInitRadioNV/ $n R h g R h g?<aA&HPNL\O$_N^NuFormDestroyCheckBox DynCBox.cNV/ $n R h g R h g?<kA$HPNL\O$_N^NuFormDestroyRadio DynCBox.cNV/ / Ef</.N&H/ /.N֜ @TOfEB/ NOR@XO?N&H/ / NO KO $_&_N^NuCheckBoxGetDataCopyFTfofNVH $n6.8. fA"HP?<,A.HPNOO JCfA,HP?<-A2HPNOO DfA.HP?<.A8HPNOO JHg/*HNO5J*NXOgt<?*L/. NO^J@POg^Hn?</. Gv`T gLp0Jg@p0 r dp0 rpR@`p0 rHhNj&V@XOr2؁`RRCFe//. p| n/0 NOU&H O g/ NO!(H XOg?/ // /.N*r:Og:<p| nRp$/ NO5< n ?p| n/0 NO^J@O gdHn?</Ofd0. @=@ nhdH nh d<|`??. p| nAHP/.NJO g˕?p| n/0 NO[&H \Og/ NO!$H XOgjvx`0p0 2dp0r2RA0`p0HrNcV@XO@RDEep, n0Dp0Hr/.N8/ NO5JDOf8`$><` ><`><RFp| np$ep| np$f>< `<<??. p| n"h/1 p|"hAHh,N$O`><0LN^NuSDDISearchTableNV/J f0<` /. BgNOE&\Og /BgNOB\O`0<&N^NuSDDIDropTableNV/ /$n f0<`6BRHxBgHnHn?.N!6Of0. @| n4$0&$_N^NuSDDIGetNumRecordsNVH :. $n f0<``BRHxBgHnHn?.N!V<Of>8Dv`&??p| nAHP/.NJO gRRRCp| np$e0LxN^NuSDDIGetFilteredNumRecordsNVH8:.xJ f0<`J?.N$H TOg2Jjg:/*NO50*E//*NO38O f/*NO!%HXO`,B`&p/NO%HXOg/*NO!%HXO`BJDfJg&jp//. pA/NO&8O f6*j`vpJgjp s dp spR@`p sHhN_V@XO8p0/NO(H XOg p0/p/3/ NO&p'O 8<RCje`8<` 8<`8<0L8N^NuSDDIInstallFiltersNVH0?.N$H TOf0<`RJg>&j g$v`pJgp/3NOXORCje/*NO5/*NO+POBjBBpL N^NuSDDIDeleteFiltersNV/HxBgHnHn?.N6Of 6. C nhdp| n 0 `p&N^NuSDDIGetTableRefNV//vHxBgHnHn?.N^6OfF8. D nhd0p| nJ g"?. p|/0 p|AHh,NO `6<0&(N^NuSDDIFlushTableNVH 8. $n f0<`hBHn?. HnHn?.N6OfD nh d6p,Hp"NOǰnXOd?.p, nHp"/ NOO ` 6<`6<0LN^NuSDDIGetTableColNameNV/ /$n f0<`BBHn?. HnHn?.N$6Of n0. h d p, D`6<0&$_N^NuSDDIGetTableColTypeNV nBPpN^NuSDDIGetTableColAttributesNVH88. <.(n f0<`DHn?HnHn?.N|:Of"6C nhd nh dp| n2. p$d<?. ?p| n"h/1 p|"hAHh,N$H Ogvx`0p0 2dp0r2RA0`p0HrN[V@XO@RDFep0 2dp0r2RA0`p0HrN[V@XO8p0/NO&H XOg*/ NO!( XOgp0/p0A//NO&O `:<` :<`:<0LxN^NuSDDIGetFieldNVH08. &n<. f0<`Hn?HnHn?.N: nh OgbHn?</HPAHHPNON?NOeO`A4HP?<A:HPNOO :<` :<`:<0L xN^NuSDDIGetRecordTable on the device has the wrong schema. Please make sure that you have the right tables installed.Table on the device has the wrong schema. Please make sure that you have the right tables installed.DvSddi_PalmDB.cSDDIGetRecord: SDDIGetRecord: DvSddi_PalmDB.cNVH8$n>. f0<`4Hn?. HnHn?.N6 nh Og0<`p ng0<`JCf:. Ep| n2. p$dB'?. ?. p| n"h/1 p|"hAHh,N`(H Og/ NO-@|xvXO`O g/./ B/ NOv6Og"6<`6<`6<`6<` 6<`6<0LN^NuSDDIPutRecord8DmResizeRecord: DmResizeRecord: DvSddi_PalmDB.cNVH0:. <. &n f0<`BBHn?HnHn?.Np>Of8D nhd nh dp| nJp$gv`??p| nAHP/.N JO gbHn??.p, n0D??p| n/0 HnNl-n-nJ.Of$K/././*/*/ t3NOORCp| np$el` >< `><0L N^NuSDDISumNVH <. >. $nz f0<`>BBHn?HnHn?.N>=@Of8D nhd nh dp| nJp$gv`??p| nAHP/.N dJO gHn??.p, n0D??p| n/0 HnN6-n-nJ.OfRJg$%nz`@/*/*/./.t'NOJOg-n-n` -R-j$%nRCp| np$e6`=| `=|0.LN^NuSDDIMinNVH <. >. $nz f0<`>BBHn?HnHn?.N=@Of8D nhd nh dp| nJp$gv`??p| nAHP/.NJO gHn??.p, n0D??p| n/0 HnN-n-nJ.OfRJg$%nz`@/*/*/./.t)NOJOg-n-n` -R-j$%nRCp| np$e6`=| `=|0.LN^NuSDDIMaxNVH $n f0<`jHxBgHnHn?.Np6OfJ8. D nhd4p| n2. p$d"?. ?. p|AHP/.NO `6<0LN^NuSDDIRecordMeetsFilterCriteriaNVH <. $n gJf0<`Hn?HnHn?.N6Of8D nB( nn nn n1n nB( nB( n0.h dx nhdn?.HmHx/.p| n/0 NO4 nJ(Of6< `<:gSE<??p| n"h/1 p|"hAHh,NѼO`6<0LxN^NuSDDIFindPositionNVH<.:. Hn?HnHn?N8p nOg0<`JDf6C n| nn  nn n1n nB( nn n0.h dj nhd`?p| n/0 p|AHh,NJ.O g?Hmp| n/0 NOO ` ?Hmp| n/0 NOoO `8<0LxN^NuSDDISortTableNV/ Hx(NO+HXXOfATHP?< 5AnHPNOO ?.N$H TOgB'Hx(/ NO'4O J$_N^NuPrvMakeGlobals4failed to create monolithic globalsDvSddi_PalmDB.cNVH0?.N:$H TOgJgd&jv`p r dp rp`p rHhNFXOJ@g p rfp r dp rp`p rHhNFXO80@r2/pJg p rJf`$p r d p rR` p rVHPHnNOJ@WDO `hpJg p rJf`$p r d p rR` p rV(H/ / NO/ HnNOͰVDO`|`|RC nhdJfLN^NuPrvMeetsFilterCriteriaNVH :. $n| f0<`dHxBgHnHn?.Nt<Of>6<8Dp. gS@gLS@gS@g`v`&??p| nAHP/.NJO fRCp| np$e`6RC`&??p| nAHP/.NhJO fRCp| np$e`6C`$??p| nAHP/.N(JO fVSCp| np$e`Dv| n608$C`$??p| nAHP/.NJO fSCp| np$ep| np$d4`4<< `<<0LxN^NuPrvFindRecordNVH8v?.N6(H TOgJgJ g$n&n J,g,v`" dpR@` HjNCV@XOr2RClev`" dpR@` HkNCV@XOr2RCle,/ / N6J,O fDCJCf|0LN^NuPrvSortCompareFuncNVH&. (.*.,.cp`dp`op` lp`pLxN^NuLongLongCompareNVH8&n(n gJf` dA`A$H dp` HkNBXO8 gJf` dA`A&H dp` HlNBlXO:vJDfJEfp`p`:JEfp`0 .?fEfp0// / NOO `p` p.@Cg(S@gTU@g]@gU@gZW@gU@gS@g4`Hx/ NOXO?/ Hx/ NOXO?/ tNO6O`Hx/ / NO6O `/ N&&/ N&, DPOf Egp`lfv``ov`Vv`P/ HnN&-n-n/ HnN&-n-n/./././.N DO f Egp`Jfv`Jov`v`/ HnNF-n-n/ HnN0-n-n DOf Egp`/./././.t%NOJOgv`x/./././.t)NOJOgv`Vv`R Df Egp`Dfv`8 Tg tfv`(v`$Ecv`Edv`p0// / NO6O 0LxN^NuPrvCompareFieldsNVH8$n &n(n gB gB g^?.N$TOf0<`L gF RJg> R&f0<`2 g, R0.hc0<`0.@| S((f0<`pLN^NuPrvLockResourcesNVH8(n $n>.|x/.Bg/.N&H O gv` g0C Jg  r d0C  rpR@`0C  rHhN>V@XOr2/0C /2AH/NO&0C  r O d0C  rpR@`0C  rHhN>V@XOr2؁`B'HxAH/NO'RO RCGe/-HmNOPO`./-6HmNOPO`/-.HmNOPO`/-HmNOPO/ HmNOHmN+zO `RDp p"FeL xN^NuOpenAppTables$SDDI_PalmDBTable.cTable.cTable.cNVH m2 P8(,v`?N<$H TOg?*?-RNdXORCDe m2Jg/(N' m2BXO mRg ?-RNTOBmRLN^NuCloseAppTablesNVH8,. F P8( =|Hn F?(?-RN86POgBnJ. gAHPNFJXOg=n F?(NJTOgfp0?N&T&H TOgB.~v`B?/N ~(H \Og$L`E dpR@` HjN8V@XO:p0'ERCDe?/ Hn F?(?-RN͒6Og=|`B'NTO g2v`"Ap0刱gp0/3N&TXORCDe/ N&FXO0.`=|`LN^NuCreateNewRecordCreate new record?NVB'.?. /.NBN^NuDeleteRecordNV<.?. /.NN^NuRemoveRecordNVH $n8. v f?<AHPN*F\OHn?*?-RNnJnPOf/-NDXO`v0.@@c/-NDXO`\J.gAvHPNDJXOgD mV P?( N TOf*?<NTOg BBHxHxNOgJ.f 0*@g??*?-RN\O`??*?-RN\O6* CgCdSj`Cf?/ Nr5@\O mV P?( N TOfJZg< mZg?<UAHPN)$\O mZhf /-ZNXO` mZhdSh mV6( Cg*Cd0@?N*TO`Cf?/ Nr\O?N*TO mVJhgB'N<NlXOvLN^NuDeleteRecordEx Table.cDelete record?Table.cNVH8(n n f m2Jg?./ N "&H\O`tHn ?,?-RNД6POf^?.?. / Nl$H POgH dpR@` HjN5 V@XO6?N"&H TOgp0// / NO&O ?. / Nx\O KLN^NuGetFieldCopyNV/ ng n f`,Hm\?.?. n?(?-RN6O g` m\&N^NuQueryFieldNV/-\N"B\N^NuUnqueryFieldNVH0&n:. Eg S6( 8LD?N!$H TOf?<pAHPN&\OB'p0// NO'$5E5CB*?Hj??+?-RNج8Og"/ N!/-HmNOHmN&O`%j 0@r2%r JL 8N^NuLockRecordAndCacheTable.cNV/ $n f`:0. je?<ABHPN&&\O f?<A6HPN&\Op0. r$_N^NuGetCachedFieldTable.cTable.cNVB'?./.?. /.NN^NuSetCachedFieldNVH0$n6. &n8.je?<AHPN%\Op0 r dp0 rp`p0 rHhN2rXO@fjJDg gp0// p0Jgp0 rJf`*p0 r dp0 rR` p0 rV/NOJ@O gD/ p0/2NJPOgp0/2N XO.?/ N^p0%|POp0 rL N^NuSetCachedFieldExTable.cNV/ /$nvJ*fv`(?*Hj?* R?(?-RN6O gv`v/ N$XO&$_N^NuCommitCachedRecordNVH0&nv`&p0$s g/ / NJPOg/ NXORCke/ NZXOfBZB-eL N^NuFreeCachedRecordDataNV np0. !|N^NuSetCachedFieldPtrNV/Jg Hn n?(?-RN6POf0.`0<&N^NuFindFirstRowNV/ /$n g4 n f / NXO`&=n Hn?*?-RNʰ6POf0.`0<&$_N^NuFindNextRowNVH $n8. BnBnv gD DfHn?*?-RN;6POgBn8.=DHn?*?-RNf6POf0.`0NOJ/-FNOJB6B2B:B>BVO`R?-p?-n?-lN6@\O`8/* N.&H XOg& S0(@ gS@g` S ( g |` mV hf S hg|/-N+\XO`Bg?*NHXO`Bg?*NH@XO`?< NJTOg?*?*N0@XO`|`z?< NJTOfl|`d?*?*NH@XO`P?*NTO`D/* NXO`80*j?/* N0\O`"NZJf|BR`?*N|TO.L N^NuAppFormHandleEvent*EventLoop.cSF-EE_SysHeapRSCEventLoop.cNVH8&n S8(> S:(6REE<\Fn?/HzHz dNu& mV!SpDГ$@JD\Og: Ъ(@A&p~>tނ// /NO&vO `\\RCDep0\Г(@B'p0.// NO' SRh> S1F6 %@ n0 LO LN^NuAllocUIObjectNVH0$n R6(6JngRCC8n ?/HzHz Nu$ mV!R R1D6p0В&@B'p0. // NO' KOL N^NuAllocUIObjectExtDataNVN^NuFreeUIObjectNV".frJzg zg+Az N^NuSetWakeupTimeNVHx/.HnNO& .N^NuGetSafeLongNVHxHn /.NO&N^NuSetSafeLongNVHx/. HnNO& n !nN^NuGetSafeLongLongNVHxHn /.NO&N^NuSetSafeLongLongNVH NOs$H/ NOx6 CXOf`6?/ NO\Of ?/ NO\O` f?/ NO\O/NOXO`LN^NuGetFocusObjectPtrNV/ /$n?. / NO6?/ NO/.?. / NO?/ NOO&$_N^NuSetLabelNVH8(.(nHnHx././.N&OgHxHxHxHnHxHxHxHxHxHxHx/?.NOFJ@O2f?. /?.NOI&H POgJf gJg/NO$JXOfNcH׮v`$Bg/.NO#$H SFAP\Og SFTBg XRC Cm CmA^HPN&"XO`6Bg/.NO6$HJ\Ogp0.// /NO&O g(`/ NO5XO KLN^NuOpenDatabaseUnable to locate Info Block.NVH0(.vHxHxHxHnHxHxHxHxHxHnHx/?.NOF?</BgNOI&H O:gp0.// NOY$H/ NOJ O g/ NO -@Bg/.NO6&H O gp0.//. B/ NOv/ NO50.nHxHxHxHnHxHxHxHxHxHnHx/BgNOGJ@OFf2vJg*Bg/.NO6&H \Of?<6A?<AHPNOO / NO"p0// NO3J@O f,`/ NO0JXOfB'N/->?<AVHPNOO Hxp0A/HnNO& nMBO g?<A0HPN\OXC/ NO"p0/?./-BNO](H Og$L/ NO!&H XOf?<AHPNf\O`bDc@Jg B'0Dr2/p0A/NO'O `B'0Dr2/p0// NO~OJfHxHnp0Y// NOvO fHxHxHxNON?NOeO K` / NO!XO`L8N^Nucomm_reallocTUtils_Palm.cUtils_Palm.cUtils_Palm.cUtils_Palm.cUtils_Palm.cUtils_Palm.cNV/ / ʗp0./NO$H XOg"/ NO!&H XOgB'p0.// NO'O f&HxHxHxNON?NOe Og/ NO+XO K$_&_N^NuxmallocNV/ <?. /.N$H JPO$_N^NuxreallocNV/ /.NO$H XOf?<wA\HPN\O/ NO0JXOgB'Nx/->?<xADHPNOO / NO+J@XOg?<{A4HPNR\O$_N^Nuxfree*Utils_Palm.cUtils_Palm.cUtils_Palm.cNVH06.=|JNg,$mN J+PNB'HxB/ NO~?/ N$H JO`XCp0/Hn/-BNOU&H O gb/ NO!$H XOf?<ArHPN\OB'p0/B/ NO~=|MB=nHxHnp0Y// NOvB'?./-BNO^O& f /-NXO JL N^Nudb_mallocUtils_Palm.cNVB'?. /.NBN^Nudb_reallocNVH0$n/ NO&H XOf?<AHPN\O`/ NO0JXOfB'N/->?<AHPNOO / NO-6Hxp0A/HnNO& nMBOg?<A\HPNn\O?</ ND$HHxHmNB/ NOv+JNOL N^Nudb_free*Utils_Palm.cUtils_Palm.cUtils_Palm.cNVH $mNv`RC$R f/-BNOO8vXO`FBg/-BNO[$H \Of?<,AHHPN\O`/ NO"XO/ NOJ@XOfBg/-BNOVRC\ODeLN^Nudb_cleanupUtils_Palm.cNV//././. ?.NO6BHnNOBHnNO0O&N^NuShowAlertNV/ $nRjB.HxHjHn?< NO$_N^NuErrorMsgNVH8..,.?<4NOo&H/./ NOxO `Z0g S@gS@g`6<5$n`6<6$G`6<7$F?/ NO:J\Of ?/ NO\O`?/ NO(H/ / NOORD Dm?<8/ NO\O?/ NO(H/. / NOY</ NO=/ NO8/ NOp0@OLN^NuConfirmMsgCustomNV0n /HnNOHxHn/.?< NhB'NNON^NuAssertFailNVHxA.HP/.?< N2B'NNON^NuFatalErrorMsgNV/ HxNO?<LNOo$HAHP?<P/ NAHPHnNOAHPHnNOAHPHnNOHn?<N/ NAHPNO @O6c?<AvHPHnNOB.O `A`HPHnNOPOHn?<R/ N8/ NO/ NOpO$_N^NuShowAbout$v 5.2.1 (Build 005) (M)NV.NO4N^NuBeepNV//v/.BgNOE(\Og/BgNOBJ@\Ofv&(N^NuDeleteAppDatabaseByNameNVH0&n<BgAHPHnBgB?</ N+H:Ogtv`$p"$nEt n/(ZHh:/ NRCO nh,eJg /.NO5XO/-:NOJ/ N0/ HnNO|#HnNB:B>OL N^NuDeleteApplication.PDBNVH $nxvHnHnHnNOO ``/ ?.?.NOJPOgJfvBg/ NO\O`Jg vBg/ NO\OHnHnHnNOJ.O fJg Bg/ NOx\OJ.fLN^NuDoButtonBehaviorNV/ / $n&n M|D|Yp-Cg( @b"Y@m` D|M`Y|M|D/p-C @b"@0;N-`.$_&_N^NuSetupDateSeqNVH0&n ~B'HxHmNO'HnHmN@x|zEEO`d.f,xR nAAf EE `:EE`0  g* 0mV 9nN lFHRJfRRfJg*NO&Hn/NOEExPO`/ NOHA0HXO@Dgf@ gD@ g`j m/ NO< XOn0n ddF=@`< f=F`. mF n/ NO=@XO` n|/ NO=@XOAAf EE `EER mD nm@ n n8 nm0?.?.NO`nXOm?.?.?./.NDO `~BgB/.N|O `L N^NuUserDateToInternalNVH8$n(n dp` HlNXOQ@gB`\ gJf` dA`A&Hx`H3 0m 9oB` R mNO&Hn/NOHnHnNvxO`HA0H@Dg@ gt@ g`Hx/ HnNO&B.HnNO0n"dHOf HxA/HA/NO&TO `ZHx/ HA/NO&XO `>HxA/HA/NO&TO `HxA/HA/NO&TO RHR mHS@B2LN^NuInternalToUserDateNVH $n |~/ HmNOEB'HxHnNO'B'HxHnNO'B'HxHnNO'vx -BO&g -Bgp`pJ@f -BgxJDf -Bgv -Bbp:` -Bbp.`p,@xz`.f l8Jg2xR`  gz pg afJfJgJf pWD`Z 0m 9n lHg S@gS@g`(HA`HA` HARRf^JfJgHnNOJXOg l`  fv`  llJg HnNOS@XOgVHnNO N&N^NuStartApplicationSelect application to run:Select application to DELETE:Index is out of bound.No records exist.Form has no records - input discarded.Must complete form before performing this action.No previous form exists.01Couldn't create app list.02Couldn't create list (type = normal).Error 03: Insufficient dynamic memory.04Insufficient database memory.05Insufficient memory to save form!06Err: Bad Type07Operation not allowed for this form.08App heap not empty! Press OK to clean up.09Invalid entry in numeric field.10App not found or invalid format - 11Invalid date or bad format - [MM/DD/YY]12Invalid time or bad format - [HH:MM:SS AM]14Extension not found or invalid: 15Extension notify returned failure.16Internal error! - 17Extension ret'd bad stack.18Table not found or invalid - 20Internal error! - Inconsistent data structures.21Unable to create a new record, maximum number of records reached.25Table(s) cannot be validated. Please make sure that the correct license key is properly installed.26Unable to load SDDI plugin - 27Incompatible SDDI plugin - 28Unsupported API - 29Bad parameter in table - 30Table won't open or invalid - 31No records in table or bad header value - 32App was created with an older or newer Satellite Forms - 33Default resource file is missing.34Cannot find needed resource - 35This table cannot be in ROM - 36Table not found - 37Table already open - 38Control does not exist on this formdb_malloc/xmalloc mismatch.NV/ /$nv RfH6*?NOo$HTO Cg Cg`"Hz/ NOPO`Hm/ NO mV!JPO/ NOtvXO&$_N^NuApplicationHandleEventNV/. /.NON^NuSF_GetNextEventNV/ $n/ NOJXOf*Hn/ HxNOJO f/ N*JXOf/ NOXO$_N^NuSF_DispatchOsEventNV/ /6.$n JCg Ce Cb;Cr+Jt;nx0@p @bX f?<AHPNL\OHjHmNOHjHnNO=j<?<"HnHx// N\JXOg2 m2 P?(.NN(+HVTOf?<uA.HPNL\O?<NOvTO&$_N^NuStartSFApp AppDir.cNVH8B.vB|ʗB2<?-TAJHPHnBgB?</.N+H:Og n SFAPg(/-HnNO/.HnNOHnN@O` n hP$g,/-"Hn2NO/.Hn2NOHn2N@B.O`~ n0(^H8((LD@?N+H2TOf?<CAHPNL\OB'p0//-2NO' m2 BpЈ!@ np0(( m2Ш !@BNBBmBmB6|BzBB-;|BZ/-:NOO=@<N4 n;hb~O`?HxN,$H \OgRG nh^e m2 P=h,gJp ?N"m2#H IJTOf?<AHPNL\OB'p / m2/(NO'O ` m2BBnBn~`z?/-:N\& C \OFORMg" ggg`, CxD?N,TOf?<A(HPNL\OB'p0//NO' F p0. m2"h #RnzJ6O f+F6p$FE Cp0(Ѓ&@x`N$ kf2 R ( g Rp0(В @?/ N+D(H \Og:%LRDpREp0+Ћ&@ Che`fJf?<ArHPNL\O`x m2!C`D0.Rn m2"h#0.nc"?<AO f/-&HnNOHnN@O ` |.`$N3J6gNJ:g/-:NOJB:XO`LN^NuLockAppStructuresR.PDBAppDir.cAppDir.cAppDir.cAppDir.cAppDir.cAppDir.cAppDir.c.PRCNVH N/-:NOO8vXO`F?/-:NO[$H/ NO/XO?NO @POf"/ NO"/ NOJ@POg?<oAHPNL\ORCDev` p0 m2"h $q g/ NXORC m2 Ph(eJ2g m2Jg/NO5XO/-2NB2XOpLN^NuUnlockAppStructures AppDir.cNV/AHPBgNOE&\OfB'/(H TOg/ ND8XOgp0?N*TOf?<ZAHPNL\O`dB'p0//NO'xv/ N=@O`0. nf=C?. ?./ N,POgB'?. / Hn/N>&H Of?<A|HPNL\O?./ N|=n0.V@R@@=@0n?/ N(.O g$GHxHnp0// NOv0.R@r2// 0T@r2// NOv/ Np0r2 E!nRC?./ N=@O* nf 8v`p0 E" ҰTp0!RCDe?//.NO?./.NOO`ZJg ?./ N\O g/ NXOJg/NXO g/ N.XOBgHx/.NO?$H TOg/ ND6XOgx?(H TOf?<UA|HPNL\O</ N&// / N`OJjg"je?<cARHPNL\Op0Ѐ02`0&H mV<( FTOfBg m2/(Nb(H/ N8O 0S@gXS@gU@gVY@gRQ@gN@gH@ g@@g@g@g@g@g@g@ g `NN`JjfJjg N *Jgx-WDH?NnJXOfJjgN`JjfJjg<NTO` mV8( B'?<?NJ\Og`v<?*?*NJ\Og|`^/ N RJXOgn`PB'NFTO`F<NTO`:p0* Њ @HPNJXOg@`"/ N .XO/NJjXOfJjgN\ g0* @g B'?/ NPOvJg / NXO` m2/(N m2!LXOLxN^NuPerformActionNV/ J. gBNGXO/.N($H/ NPO$_N^NuPerformControlActionNVH8&n|Bn m2$hJkg/ NX?-RNr m2B\OJkg f6v\C?N*TOfB.`B'p0//NO' E0O `,/ / NL?+/ N*=R/ N?-RNrOv~`p0E0.G(EI<=j8*D Dg0*@gp0*A-H`.?*N<-HTOf?<A>HPNL\O/.N-HXO m2 PJh4g& m2 Pp0(4 m2А @HP/.NOJ@POfx Dg:Hn?.?N>TO//.N8$H?./ NP)H Og/ NXO DfSG ESP`?N>89n9DTORCRGke EJPf/N?-RNrz\O m2!EJgB E?Hh?-RNlv~PO`$p0E<?N>$H/ N5@RCRG\Oke.LN^NuInstallFilters Action.cNVH8(nx g6n \C?N(TOgB'p0//NO'p\// /NO&vO`pEp&DGJg j d jp` jHhNXOJ@g^ j d jp` jHhNXO:?Jg jJf` j d jR` jV/NP'H\O`BRCTeX D0. P DL8N^NuCloneFiltersNV/ /$n g*v`pJ gp/2 NXORCRe/ NXO&$_N^NuDeleteFiltersNVH8&n.. |`xp0(GI?N>*TOg^v`VpE E0(RfB0*lf8Jg/*NBXO0R@8@gp/A// NO&O SSSCRCSeRF GheLN^NuKillRepeatedFiltersNVH 8.v mV P?( N>$H TOgJ Dg / ND@XOd8J. g NJg*`JZg /-ZNXO?NJ. TOgN'nNvLN^NuGotoRowNV/NJfp`,. ?.NXXOfJ. g <N^TONZN&N^NuAdvanceByPageExNV<?.NN^NuAdvanceByPageNVH8>. B.v˙x0-nVD|?.N7$H TOf/-NXO`J-f(NJgJf mVJh f|/(NOx=@XO R h g R?( N>&H TOf?<AHPNL\O GfB'/ N6x\O`TJ-f< R"mV"Q0) h f* mV?(/ N8J\Og mV6(`/ N6XO`/ N6XO`6<~ Cf< Gg6 Gf/-NXO`J-fJGfB'/ N6x C\OgJgBB mV/(NOr mV(hJ-XOfJg <NTOJ. g Jg5m +JV;n?NJ-TOg B-BgN4TOJg<Bg/ NPO` <N p0./ mV/(NO JgN$NNZ|B-.LN^NuGotoNewForm Action.cNV/ /v mV P?( N>$H TOg mV?(/ N8J\Ofv&$_N^NuCurrentRowInvalidNV/ / $n R0(W@g[@gPU@gS@gzS@gv[@g` Rp0(В @Jhg Rp0(В @p0( Rr2(ҒҀ&A` Rp0(В @JPg Rp0(В @p0 Rr2(ҒҀ&A` Rp0(В @Jhg Rp0(В @p0( Rr2(ҒҀ&A`f Rp0(В @JhgT Rp0(В @p0( Rr2(ҒҀ&A`2 Rp0(В @Jhg Rp0(В @p0( Rr2(ҒҀ&A K$_&_N^NuGetControlActionNVH8$n~p0*Њ&@:<8$H TOg5n$_N^NuSetCurrentRowNumNV mV!n1n /.NNNBBHxHxN<NB-eJ.OgBgN0TO mV1|N^NuInitializeFormNV?. /.` N|N^NuFarCall_ProcessScrollbarNVH 6.xz0. @f C gr C gl Cgf Cg`N/N$H mV hXOf0 g, R hg R h f R hg/-NxXO`6Jmg,p0-/N;RXO`x C g Cfp`p?NTO` <N^TO`L8N^NuProcessKeyHitNVH ~B. mV:(8( P?( N>$H0.TOY@g4Y@g,Q@g@g&@g @ g`6 mV P0(@@e$`JDf gBJ. g mV P0(@g*|0.Y@gY@gzQ@gN@g@g2@ g`/ N6XO`|/ N6XO`p?/ N6<\O``?/ N6<\O`P mV P0(@@d6<RF`6?/ N6\O`(JDg 6<F`?/ N6 mV P<(F\O gV CfP ng n@f^J. gT m2 P0(&@gH mV P0(@g8</ N6| C\Og?N@0;N444444484&88/ NXO`?. / N\O`vxJg </ N\OLN^NuProcessControlSelectNV/ / mV P?( N>$H TOf <N^TO`,NJg$./ N6 C\Og<<?N\O&$_N^NuFormCreateRowNV/ / mV P?( N>$H mV6( TOg Cf <N^TO`L.?/ NJPOg: mV6( Cf,J-f& P0(@fB'/ N6?NpNNPO&$_N^NuFormDeleteCurrRowNVH mV P8(v`e8p-CAX&H n /(/(/./.HnN&.(ORn n@mfJg n !EJg n !DLN^NuNVB/.HnHn N nN^NuNV/ $nJ ld/./. Hn NJO l&/./.HnNB/ HnHn NO`rB/ HnHn N/*/*/ NO`NJl4/./.HnNB/ HnHn NJ/*/*/ NO(`B/ HnHn N&O J$_N^NuNV/.BHnHn N nN^NuNV/ $nJ lb/./. Hn N6JO l$/./.HnN/ BHnHn NO/ BHnHn N/*/*/ NO`.Jl/./.HnNO / BHnHn N`O J$_N^Nu o / !@ / Nu o / !@ / Nu o!o  /  /Nu / gepNu /gdpNupNu$/ /"/ gmpNupNu o!op Nu o /!@gp Nup NuH0tN"` LL Nu$HB&HCCHBBBЂL NuH0tN"` LAL Nu$BBHBf6B@H@g4HB04 L Nu4B@H@HB&rԂрeRQ L NuJl DJlDNJmNDNDNuH0tN"` LA L Nu$BBHBf6B@H@g4HB0B@H@L Nu4B@H@HB&rԂрeQL NuJlDJmNDNDNuNV/ $m` g+R`?A%HBA%HFA%HJA%HNA%HRA%HVAh%HZA.%H^A"%HbA(%HfAd%HjA%HnA%HrAj%HvA,%HzA`%H~A%HA%HA%HA%HA%HAT%HA^%HAT%HA%HA%HAb%HA%HA%HA%HAJ%HA,%HA%HA%HA%HA>%HA%HA%HA%HA %HA%HA%HAD%HAv%HA%HAj%HA%HA%HA%HA%H A %HA%HrA%HA >%HAp%HA|%HA%H"A%H&A6%H*A "%H.A8%H2A%H6A%H:A%H>AB%HBA%HFA%HJA%HNA %HRAX%HVA:%HZA 4%H^A%HbA%HfA%HjA%HnA%HvA%HzA%H~A%HA%HA%HA%HA8%HA%HA%HA~%HA %HA"%HA%HA(%HA.%HA4%HA:%HAL%HAR%HAX%HA^%HAd%HAj%HAp%HAZ%HA%HA%HA%HA%HA%HA<%HA%HA%HA%HA%HA%HAb%HAP%H A%HA%HA%HA%HA%HA%H"A%H&A%H*An%H.At%H2?<6N"+HO f / NXO`Hx6/ B/-NOv/ NO K` g/ NXO`$_&_N^NuAllocExtensionRecordNVH0$n&n6. C Cg C f< f p0Jf g(p0Jf gp`p8 Cfm`m/ ?. /*NO L N^NuSetLinkagePtrNV/ $n f?<APHPNL\OHxHnp0. "*t ҂Ҁ//*NOvO$_N^NuLinkage_WritePtr Extension.cNVH8&n(. vʙ f` f2 +X$@ gNg$Kp $jf`v/-N@XO`jp fv`^(k f?<AlHPNL\O d@ $t g4/ ?</ NlO Qg SgSg`/./.NPO`NLN^NuNotifyExtension Extension.cNVH (.&. ..,.z$m`,Jg * g//// NpOfp $R fLN^NuNotifyExtensionsExNV/ / $m`H * g0Jg /* NO"XOJ g /* NOaXOJg /*NOJXO&R/ N$KXO fBBmBmJg/-N.BXO$_&_N^NuUnloadExtensionsNVH8&.(n &n$mp WD`,Jgp g  jJg/ / // NO$R fLN^NuCallEventHooksNV n h hN^NuGetExtensionControlNV n h h$N^NuGetInstanceDataPtrNV n h!n $N^NuSetInstanceDataPtrNVH8(n n h$h gv R hfl Rp0(В&@JkgZ/ NO6x8+؋ Dp0Є$@XO`80C// / NOJ@O f 2=0f 0R@H J`/ NOR@r2XOJfđLN^NuGetConfigVarNV/v . bJ@0;N"(60&-V`,&-6`&v6-r`&-t`v6-x`&-Z` vTR &N^NuGetGlobalDataNVH $nx . b@0;N*4<BL\T Rx8( ` mVx8(`r Rx8(`hx8* ``(*`Z Rx8(`Px8* `HA(`@ m2 P:((xv`,0@r2 m2"h fp0"h (1`RCEe L8N^NuGetFormHeaderDataNVH $nx . b@0;N$.8BLV\ Rx8(`| R(( `t Rx8(`j Rx8(`` Rx8(`V Rx8(`L Rx8(`B(*`< mV P:(xv`(0@ mVAfp mVA(`RCEe L8N^NuGetControlRecDataNV m2 Pp0(` m2А"@p0.p0Љ @N^NuAppDesIndexToExtensionNameNVp0. m2"h qN^NuAppDesIndexToExtensionRecNVBBHxHxN?<NpN^NuNotifyRecCreateNV/./. Hx /.NvN^NuNotifySfxNVH0&n$kB'/. N\Og/ ?</ N@p.nn|`:D>DGJ.fp.@o~.p2.E@nJ.g-nf 0`SEJEn`0SnJnnBJGop=@/.NOGnXOdZ.Bn` 0BSnJno p=@/.NOǰnXOe`BSGJGo(p=@/.NOǰnXOe`|`|J.g&n Ef 0fRzSC0S@@ Do Ddmp`p> Do D mp`p=@JDlp`pT@nG:p2.RAE@nlJ.g-SCBJCoFp=@/.NOEnXOd,.B`BSCJCop=@/.NOEnXOee0D// NOPO` p?ABHP/ NOp0O .WDLN^NuNormalizeNumberUtils.cOverflowNVB'HxPHmNO'/.HmNO/. HmNOr2AXOHpNOHmNO @POe?<lA$HPNL\OHmNN^NuInfoMsgIntUtils.cNV/ / &n f`$/ NOR@XO?N$H TOg / / NOPO J$_&_N^NuCloneStringNV/ / &n f`*p0T?N$H TOgp0T// / NO&O J$_&_N^NuCloneBlobNVH . . d p. H`p /.HnN\ O e dzvE`2 eg Efz`&Jg 0m 9nRC` z` .fxRJfJfPJf4HnNO @XOd$AtHPHnNOPO`AdHPHnNORCPOp@lHnNO @XOe--HnNOHn/.NOOLN^NuFormatNumber.0NV/ /$nHjNO..B*HjNOH@nnB*/ NO6p.O g:0<nHg. Cpe( Cd"0@..?.NOcTO`p&$_N^NuInternalDateToSysDateNV/ Hn/.NOb?<N$Hp.?0<nH?p.@p?/ N& JO$_N^NuSysDateToInternalDateNV/ $nR n0. @H// NOSp nH/HjNOS*p nH/HjNOS*O$_N^NuBuildInternalDateNV/ /$n fp`:/ Nr/ HnNpGGvPO`&/ HnN|GGvPO`6G`B.v Cf / NO6XO?N(H TOf?<ARHPNL\Op0// / NO&O Jg E0 LL8N^Nu ConvertDisplayToInternalFormatExUtils.cNV/ /$n0n bp`"p0. Ѐ62gp0Њ @HPNXO`p&$_N^NuFireEventExNV/ mV Pp0( mVА$@?./ N\O$_N^NuFireEventNV/ m2 Pp0(f m2А$@?./ NV\O$_N^NuFireGlobalEventNVH0&n dpR@` HkNV@XO6?N$H TOf?<!A4HPNL\Op0// / NO& JO L N^NuCloneDbItemUtils.cNV/ ?.N$H TOg mVA r2 rN`0<$_N^NuOsIndexToAppDesIndexNV mV P0.hdp"mVC IN^NuAppDesIndexToControlRecNV/ m2 P0.h(dp0. m2"h $q J$_N^NuAppDesIndexToFormNVH0>.<. 8. mV P:(v`.p$mVEJDg Rhf??/ N0JPOg&J`RCEe KL N^NuPointToControlRecNV"npfp`6 Q0. he( Q0. hd Q0.he Q0.hdp`pN^NuPointInControlNV0. N^NuV20_GetFirstFieldNV/ /$n6*5n /.N?./ Nv5CO &$_N^NuV20_CommitItemToRowNVH8(n6.??. / N$H?/ NrOADg QAgQAg` dp` HjNXO=@g\R@?N&H TOf?<`AHPNL\Op0./ gJf` dA`A// NO&p0.B3O `$?<N&HBTO`?/ Hn/ N&HO g/ NXO KLN^NuV20_GetRowItemCopy Compat.cNV/ n P?(?./. N$H/ /.N/ NO$_N^NuV20_LoadControlFromRowNVH0/.N$H dp` HjNXO?N&H \Odp` HjNXO6p0/ gJf` dA`A// NO&/ N KOL N^NuV20_SysDateToInternalDateNVH0/.N$H dp` HjNXO?N&H \Odp` HjNXO6p0/ gJf` dA`A// NO&/ N KOL N^NuV20_SysTimeToInternalTimeNV?././. NTN^NuV20_LoadCtrlObjFromRowNV?././. N"N^NuV20_LoadDropListFromRowNV?././. NN^NuV20_LoadFieldFromRowNV?././. NN^NuV20_LoadInkFieldFromRowNVB'N4A*HP?<ABHPNON^NuV20_LockRowItem,Function LockRowItem is obsolete.Compat.cNVB'N4A2HP?<ARHPNON^NuV20_ResizeLockedRecord4Function ResizeLockedRecord is obsolete.Compat.cNVB'N4A*HP?<ADHPNON^NuV20_UnlockRowItem.Function UnlockRowItem is obsolete.Compat.cNV/. /.NO/./.NON^NuSanitizeDbNameNV/ /$nAhCp?"QB/. /.HnNHnNOr2AA-HHnNO2<@=ABO`HnHntNOH6POg p-@`Hn?<AHP?.tNOH6O fB`tHnHn/.tNOH6O gp-@`RHn/.NOJ@POf@BBHn/ Hn?.t'NOH6OgHxHxHx?NOeBOp-@pf/.tNOHXOpf* .&$_N^Nu'FindDatabaseAndCopyFromSecondaryStorage/Palm/Launcher//Palm/Launcher/NVH (./NO$SXOf ?. /NO6$H\O/NO6/ NO5PO`?. /NO%\O/NO6XO?NO 80@TOgp`pLN^NuIsDbInRomNVH8(n&n$n gBBR/ BgNOE&\Of/ ?<NOE&\Og4Jg(?/N>J\Of Rf gJ.gv `,HnBg/ m2 h8($m2$jP`Rf HjNXO`>p0*A$H0SDJ@f`( C,e ?N^/ NO_XO`^Hn/ NOOp .POgH/ NO4XO`>/ NO3XO`4Hn/ NOOp .POg/ NO* `6`0*`(*` * `NJg p* `p`pL N^NuNVNJg/.tNOXO` n-h nN^NuU.,d@?EB_ BDx@F)>Y9H=c)\JQ~dLc DNw.=PQ_Rk )YTI%}VJ0GƔXƠ4*Zb[-]pKsy_5.Pa&%oc:REeNNTsga#Jit ׃bZNADNAjNANANA&NAtNANANANA NA\NAvNA >NA NA!:NA&jNA' NA'\NA(4NA*NA*xNA,"NA,NA-NA-tNA-NA-NA.NA.hNA.NA.NA.NA0NA0,NA0NA1NA1NA1NA1NA2NA26NA2TNA2dNA2NA2NA3NA34NA3NA8NA8NA9>NABNAC,NACNAGNAHDNAHNAMNAMNAN:NAOVNAPNAPpNAPNAQPNAQNAR\NARNARNASBNAUNAGhNAGNAINAJPNAJNAJNAKNAL"NALRNAMNAMNANnNANNANNAOFNAONAP NAP8NAPNAQ\NAQNARPNASNATNATFNATNAU8NAVNAVTNAVNAW NAW0NAWdNAX>NAX~NAXNAYNAYLNA\ZNA]rNA^NAb~NAc^NAcNAcNAd6NAd`NAdNAdNAdNAe\NAeNAgNAhvNAhNAiNAjNAlNAmNAmDNAmNAnNAoNAoNApNApNAqNAqNAr>NArxNAslNAsNAtNAuNAwNAyNA{NA|NA}4NA}NA~NA"NA NAvNANANABNANANANANA"NAXNANANANA((EhbBhBpENa/B0D0, C0D1 C1E3 C3E3 B5@E6BC6€B7CW}C+Error: Couldn't create app list. Couldn't create list (type = normal).Insufficient database memory.Insufficient memory to save form.Bad type [^0].Operation not allowed on this form.App heap not empty. Press OK to clean up.Invalid entry in numeric field.App not found or invalid format [^0].Invalid date or bad format.Invalid time or bad format.Extension not found or invalid [^0].Extension Notify returned failure.Internal error [^0].Extension returned bad stack.Tabel not found or invalid [^0].Inconsisten data structures.Unable to create a new record, maximum number of records reached.Table cannot be validated. Please make sure that the correct license key i properly installed.Unable to load SDDI plugin [^0].Incompatible SDDI plugin [^0].Unsupported API [^0].Bad parameter in table [^0].Table won't open or invalid [^0].No records in table or bad header value [^0].App was created with an older or newer Satellite Forms [^0].Default resource file is missing.Cannot find needed resource [^0].db_mallos/xmalloc mismatch.Table cannot be in ROM [^0].Table not found [^0].Table already open [^0].2LQ tHvAbout Satellite FormsNs1234567890123456789012345678901O*XAll Rights Reserved.P<11234567890123456789012345678901QM 1997-2003 Pumatech, Inc.Ri1234567890123456789012345678901Sqp$ OKVG0 d6dR4 #FRTL ND,U(-X-.C1/P60S<1G2KI3GRRecordsGoto FirstGoto PrevGoto NextGoto Last-Create...Delete...EditUndoCutCopyPasteSelect All-KeyboardGraffiti Help ?@~`@88xx?<@@@8@x@xOy=?y89@D=?yx{?<L/J\Of Rf gJ.gv `,HnBg/ }}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}  @  @  SysUIAppSwitch failed --Out of memory --SF RDK engine cannot be found --App name tSTR resource is missingRDK tSTR resource is missingSystem IncompatibleSystem Version 3.0 or greater is required to run this application.OKL֎StartupCode.cE ror launching a plication@((Unable to start application^1 ^2.OKATP 3Eatp30000$ATP_3SF52RDK00 ?<0.01.1MathLibcrsr3ptaP ,F,F,FlibrMthLlibrntAINBtverJHzNu/ $o N$Bp$_NuANu4hlptx|  $(,0NNDNNNnPNntNnNnNnNo No0NoTNolNoNoNoNoNp NpDNphNpNpNpNqNq8Nq\NqNqNqNqNrNrDNrhNrNrNrNsNsNs(NsTNsNsNsNsNsNtNtHNttNtNtNtMathLib/ / ocp`\?/ NO&H$k TOg/ NO!&HRSXO`0HxNO$H XOfp`&'J/ NO!&HBg/ NO6O / NO"pXO$_&_NuH2&/?/NO&H$k TOfp`*/ NO!,HSV C0/ NO" CJPPOf / NO+BXOpLLNupNupNuH Oh$o(/& ?m*/ f Jo BB` $@ !%|TD-` ////////Ho0t5NOO/(/(////////Hot5NOO/(/(/ t6NOO` J ?l, <`n$?!%|TD-` "////////Hot4NO/////< /@lNB/ lNB/@l"////tNOJPOf$?B`J////////Hot4NO/////<8/!HoDt3NOO/(/(////HoHo$t3NOO/(/(////HoTt4NOO/(/(/<Qw/(/|5,/|.D0/|4/|p&8/|_~A@l"//l//ltNOJPOf$h%ol`//l//l//t//tHo`t4NO//////p//pHolt4NO//|//|/HoPt3NOO/(/(////HoHt4NOO/(/(/<a/<*Hopt3NOO/(/(////Hoht4NOO/(/(/</tD-\B`/|pHot4NOO/(/(tNOPO/HotNO////B/pHot4NOO/(/(tNOPO/HotNO////B/p////Hot4NOSQYO(Jl(`BB|*چ& &@$@`R AT/(/(A\/(/(Hot4NOO/(/(////Hot3NORPROPno A !oSJln /4gSgSgSg`fBB(&`(A/(/(////Hot3NOSQOJlJf/o /o$` ////Hot2NO/P,/h0O o( !o$`BB(&`(A/(/(////Hot3NOSQOJlJWDHH*g/o/o` ////Hot2NO/P$/h(O o( !o////////Hot5NOx&O`(A/(/(////Hot3NORPOoJg/o/o` ////Hot2NO/P/h O o(!o!o `(&`|A&H/(/( SA,H/(/(Hot3NO$K/////./.Ho t5NOO/(/(/*/*/ t3NO'o 'o$SQO(Jn(&`|A&H/(/( SA,H/(/(Hot3NO$K/////./.Ho t5NOO/(/(/*/*/ t3NO'o 'o$SQO(pn~BB(&`(A/(/(////Hot3NOSQOplJf( o( !o!o!o !o!o`B//////0t2NO//// o*p/|tz(/ & >0l//$//$tNOJPOf(/$ "Rf4//$//$HoNvO ////B/Hot3NOO/(/(////Hot4NOO/(/(/<۸/<HoHt3NOO/(/(////Ho@t4NOO/(/(/<U/0d`B/f7iHot4NOO/(/(/0lNB///\//\B///\//\B/RD/Jf\//t//t////Hot5NOO/(/(//t//tHo8t4NOO/(/(///// t5NOO`/////////<5y lBB////B/RD/0lNB/0lJBB//d//d/<u/<~7RD/L/|C/o/o./,o(/* f$?B` n" fJf n f$ g ///////// t3NOO`Jlr C@mp&@`d ?m\,rpo$p4/@ & "/ 㨽f2pr&A`& f"p/@& "/㨺f pr&A f, f f ///////// t5NOO` ?m(Jm/oH/oL`BHBL$H%oL`Jl"////Hot2NO/PL/hPO `B@BD$@%oD`Z ?f2Jl ////B/T HoTt4NOO/(/(Hot5NO////////Hot3NOB////////Hott5NOO/(/(////Hot5NOOx`z l&B//Hot4NOO/(/(HoHt3NOO/(/(A/(/(Hot3NO/HotNOA/P\/h`/(/(////////Hot3NOO/(/(Hot3NOO/(/(////Hot3NOB//////|//|////////Hot5NOO/(/(Hot5NOO/(/(Hoxt5NOO/(/(////Hot5NOO/|?XB\ S"f /|XB\/o/oB//d//d////Hot4NOO/(/(////////Hot5NOO/(/(//L//LHoXt4NOO/(/(Ho(t3NO//P//P////Hot4NO//////L//LHot3NO&/(/ @Of7iHot4NOO/(/(//|CPH//l//l//T//THoXt4NO&/\ rN)x/@\O` rNr*x/@H//l//l//T//T//\//\Ho@t4NOO/(/(HoPt6NO//`//`//`//`HoDt4NOO/(/(/<_/p3o& f0//$//$//,//,/ t3NOO`/D pЃrF†$& 'o$L xNu"/ NuMathLib1.1Eatp30000#ATP_3 ,F߼,F,Frsrcatp3TbmpHZ G/ >   >??|8011!!ATP 3116937!ATP3A#???> }}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}  @  @  00!Installing...